



## TOPICAL REVIEW

## Peptide based drug delivery systems to the brain

## OPEN ACCESS

RECEIVED  
9 March 2020REVISED  
29 April 2020ACCEPTED FOR PUBLICATION  
4 May 2020PUBLISHED  
21 May 2020

Original content from this work may be used under the terms of the [Creative Commons Attribution 4.0 licence](https://creativecommons.org/licenses/by/4.0/).

Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.



Yamir Islam<sup>1</sup>, Andrew G Leach<sup>1,2</sup>, Jayden Smith<sup>3</sup>, Stefano Pluchino<sup>4</sup>, Christopher R Coxon<sup>1,5</sup>, Muttuswamy Sivakumaran<sup>6</sup>, James Downing<sup>1</sup>, Amos A Fatokun<sup>1</sup>, Meritxell Teixidó<sup>7</sup> and Touraj Ehtezazi<sup>1</sup> 

<sup>1</sup> School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, United Kingdom

<sup>2</sup> Division of Pharmacy and Optometry, The University of Manchester, Stopford Building Oxford Road, Manchester M13 9PT, United Kingdom

<sup>3</sup> Cambridge Innovation Technologies Consulting (CITC) Limited, St. John's Innovation Centre, Cowley Road, Cambridge, CB4 0WS, United Kingdom

<sup>4</sup> Department of Clinical Neurosciences, Clifford Allbutt Building - Cambridge Biosciences Campus and NIHR Biomedical Research Centre, University of Cambridge, Hills Road, CB2 0HA Cambridge, United Kingdom

<sup>5</sup> School of Engineering and Physical Sciences, Heriot-Watt University, William Perkin Building, Edinburgh, EH14 4AS, United Kingdom

<sup>6</sup> Department of Haematology, Peterborough City Hospital, Edith Cavell Campus, Bretton Gate Peterborough, PE3 9GZ, Peterborough, United Kingdom

<sup>7</sup> Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Baldiri Reixac 10, Barcelona 08028, Spain

**E-mail:** [t.ehtezazi@ljamu.ac.uk](mailto:t.ehtezazi@ljamu.ac.uk)

**Keywords:** blood brain barrier, drug delivery, brain, nanoparticles, nanotechnology, shuttle peptides

## Abstract

With estimated worldwide cost over \$1 trillion just for dementia, diseases of the central nervous system pose a major problem to health and healthcare systems, with significant socio-economic implications for sufferers and society at large. In the last two decades, numerous strategies and technologies have been developed and adapted to achieve drug penetration into the brain, evolving alongside our understanding of the physiological barriers between the brain and surrounding tissues. The blood brain barrier (BBB) has been known as the major barrier for drug delivery to the brain. Both invasive and minimally-invasive approaches have been investigated extensively, with the minimally-invasive approaches to drug delivery being more suitable. Peptide based brain targeting has been explored extensively in the last two decades. In this review paper, we focused on self-assembled peptides, shuttle peptides and nanoparticles drug delivery systems decorated/conjugated with peptides for brain penetration.

## Abbreviations

$\alpha$ -Syn	$\alpha$ -synuclein
ABCB1	ATP-binding cassette sub-family B member 1 (ABCB1)
AC	Astrocyte
AChR	Acetylcholine receptor
AD	Alzheimer's disease
AF6	IL1-fused gene from chromosome 6 protein
AFM	Atomic force microscopy
AMT	Adsorptive-mediated transport
ANG	Angiopep
ApoB	Apolipoprotein B
ApoE	Apolipoprotein E
AuNP	Gold nanoparticle
ASNP	Alginate-stearic acid nanoparticles

B6	CGHKAKGPRK peptide
BBB	Blood-brain barrier
BCSFB	Blood-cerebrospinal fluid barrier
BSA	Bovine serum albumin
CNT	Carbon nanotubes
CMC	Critical micelle concentration
CNS	Central nervous system
CSF	Cerebrospinal fluid
DLS	Dynamic light scattering
EAE	Experimental autoimmune encephalomyelitis
ECs	Endothelial cells
FBS	foetal bovine serum
FITC	Fluorescein isothiocyanate
g7	7-amino acid glycoprotein, GFtGPLS (O- $\beta$ -d-Glucoseglucose)CONH <sub>2</sub>
GE11	CYHWYGYTPQNV1 peptide
GSH	Glutathione
HD	Huntington's disease
HIFU	High-intensity focused ultrasound
HuHtt	Human huntingtin exon 1
IFN- $\alpha$	Interferon- $\alpha$
IFN- $\gamma$	Interferon gamma
i.v.	Intravenous
Lamp2b	Lysosome-associated membrane protein 2b
LDLR	Low-density lipoprotein receptor
LRP-1	lipoprotein receptor-related protein 1
MCAO	Middle cerebral artery occlusion
miniAp-4	H-DapKAPETALD-NH <sub>2</sub> peptide
MMP	Matrix metalloproteinase
MND	Motor neurone disease
MOR	Opioid receptor mu
MS	Multiple sclerosis
MSC	Mesenchymal stem/stromal cell
MWCNT	Multi wall carbon nanotubes
nAChR	Nicotinic acetylcholine receptor
ND	Neurodegenerative Disease
NP	Nanoparticle
NIR	Near infrared
NVUs	Neurovascular Units
NW	Nanowire
PAH	Poly allylamine hydrochloride
PD	Parkinson's Disease
PEG	Polyethylene glycol
PepH3	AGILKRW peptide
PLA	Poly(lactic acid)
PMNP	Polymeric nanoparticles
pSiNPs	Porous silica nanoparticles
RES	Reticuloendothelial system


ROS	Reactive oxygen species
RVG	Rabies virus glycoprotein
RVG-29	YTIWMPENPRPGTPCDIFTNSRGKRASNG
SWCNT	Single wall carbon nanotubes
SE	Status epilepticus
SEM	Scanning electron microscopy
siRNA	Small interfering RNA
SNALP	Stable nucleic acid lipid particle
SPION	Superparamagnetic iron oxide nanoparticle
t-MCAO	transient middle cerebral artery occlusion
TAT	Trans-activating transcriptional activator
TEM	Transmission electron microscopy
Tf	Transferrin
TfR	Transferrin receptor
TJ	Tight junction
TNF- $\alpha$	Tumor necrosis factor- $\alpha$
WHO	World Health Organisation
ZO	Zonula occludens (a.k.a. tight junction protein)

## 1. Introduction

The central nervous system (CNS) comprises the brain and the spinal cord. Any injury or damage to the CNS affects its normal functioning and may lead to permanent disability in many cases, due to a largely limited ability for neural tissue regeneration in humans [1, 2]. The broad term ‘Neurodegenerative Diseases’ (NDs) covers a range of pathologies, principally affecting neurons in the brain and causing significant neuronal dysfunction, neuronal death and neuronal loss. NDs once established are irreversible and sapping conditions resulting in progressive degeneration of neuronal cells [3]. The signs and symptoms are diverse in range, depending on the affected part of the brain. The cause of an ND is often unknown but can involve a complex convergence of multiple molecular mechanisms; and disease progression is usually unpredictable. NDs include a number of conditions: Alzheimer’s disease (AD) and other forms of primary dementias, Multiple Sclerosis (MS) and other forms of chronic inflammatory neurological disease, Parkinson’s disease (PD), Motor Neurone Disease (MND), Huntington’s disease (HD) and ataxias [4]. The World Health Organisation (WHO) reported that NDs affect around 0.1 billion individuals (24 million individuals suffer from AD and other dementias) [5] all over the world, and the incidence is on the rise as average life expectancy is increasing. Around 850,000 people in the UK are affected by dementia, costing the healthcare system over £26 billion a year [6]. In the US nearly 100 million people are affected by NDs costing around \$724 billion in 2014 [7]. It is estimated that the cost of AD would be over 1 trillion dollars worldwide [8]; and the estimated number of people with dementia will reach 131.5 million by 2050 [9] in the absence of effective therapies. Just in Europe, the annual cost of neurological disease reaches 800 billion Euros per year, with a majority attributed to direct costs [10].

The brain is one of the most vital and sensitive organs in the body, which, to perform its functions in an appropriate way, needs nutrients and gases [11]. Due to its pivotal role and functions, it is protected in a number of ways, including by the skull, the outer skin, three layers of meninges and the blood-brain barrier (BBB) [12]. The BBB is a layer of endothelial cells (ECs) associated with pericytes (PCs) and astrocytes (ACs) and acts as a separator of the blood from parenchymal cells, thus preventing penetration of drugs into the CNS. It therefore protects the brain from overexposure to substances such as potassium, glycine and glutamate, which, in high levels such as found in pathological conditions, are neurotoxic [13, 14].

Despite many advances in drug delivery systems that target the brain, it is still a challenging area. The failure of therapies administered via an intravenous (i.v.) or an oral route is often due to their inability to cross/penetrate the brain parenchyma. The use of peptides for drug delivery to the brain has been extensively explored in the last decade. Self-assembled peptides, shuttle peptides and peptide-decorated nanoparticles have been reported to effectively deliver drugs in the brain. This review covers peptide based drug delivery systems for the brain and future prospects.



**Figure 1.** BBB composition and pathological conditions. (A) In normal states, the BBB comprises vascular endothelial cells connected with TJs and the PCs layer. A basement membrane linked with AC end-feet surrounds the endothelium. (B) Increased permeability of the BBB in pathological conditions results from high matrix metalloproteinase (MMP) activity and increased reactive oxygen species (ROS) and nitric oxide (NO) levels. Cytokines and chemokines are released and then activate microglia/macrophages, leading to basement membrane degradation, TJs disruption and an inflammatory response.


## 2. Blood-brain barrier

Figure 1 is the schematic representation of healthy and diseased BBB. Numerous gateways have been reported to provide access the brain; the most significant are through blood stream or by getting access to the cerebrospinal fluid (CSF) circulation. Penetration of any molecules administered via the parenteral route is controlled by the BBB, the blood–cerebrospinal fluid barrier (BCSFB), arachnoid barrier and circumventricular organ barrier. However, drug molecules up taken by the brain are flushed back towards the blood through the return of the CSF to the blood or transporters on the BBB [15]. The BBB acts as a guard filter that prevents the uptake of large-molecules and more than 98% of pharmaceuticals [12, 16] and small-molecule drugs [17]. Small molecules that are lipid soluble, electrically neutral and weak bases may be able to diffuse passively across the BBB.

Thus, the BBB, with its extensive blood capillary network, is considered the most important barrier that controls a molecule's access to the brain parenchyma. Neurovascular units (NVUs) comprising endothelial cells, extracellular base membrane, adjoining pericytes, astrocytes, and microglia (although not a structural component of the BBB, are often included in the NVU as they influence barrier function in response to injury and disease [18] are integral parts of the BBB supporting system [19]. NVUs collect signals from the adjacent cells and generate functional responses that are crucial for appropriate CNS function [20, 21]. Both tight intracellular junctions (i.e. zona occludens, characteristic of the BBB) and the absence of fenestrations limit the permeability of drug molecules [22].

Various transport routes have been reported by which solutes and drug molecules can cross the BBB, [23, 24] as shown in figure 2. Diffusion of substances across the BBB can be generally categorised into paracellular (namely the transfer of nutrients/drugs across an epithelium by passing through the intercellular space between the cells) and transcellular (namely the movements of solutes through a cell). In order to cross the BBB by passive diffusion, various parameters play pivotal roles. Molecular mass is an important factor and the ideal molecular weight reported to be suitable for passive diffusion is <400 Da [25]. A value of between 5.0 and 6.0 for the log of the octanol-water partition coefficient ( $\log P_{o/w}$ ), a measure of lipophilicity, is suitable for passive diffusion [26].

Compounds that are lipophilic, neutral or uncharged at pH 7.4 and have less than 8 hydrogen bonding groups are more suitable to cross the BBB [27]. In another study, reported by Partridge in 2012, [28] it was found that small drug molecules can cross the BBB if their molecular mass is less than 400 and they have the ability to form 8–10 hydrogen bonds. Unfortunately, it has been reported that more than 98% of drugs for the CNS are unable to cross the BBB adequately to attain the minimum therapeutic concentration [12]. Several invasive and non-invasive approaches have been anticipated to evade the BBB and enhance drug delivery to the CNS.



### 3. Novel shuttle peptides


Shuttle peptides facilitate the influx of a diverse range of small molecule cargoes across the BBB. The concept of shuttle peptides for BBB was coined by William M Pardridge in the mid-1980s [29]. Small synthetic peptide shuttles (comprising natural amino acids) have been reported to cross the BBB. For example, the short rabies virus glycoprotein (RVG), RVG-29 (YTIWMPENPRPGTGPCDIFTNSRGKRASNG), binds exclusively to the nicotinic acetylcholine (nAChR) receptor found on neuronal cells and on the endothelial cell lining of the BBB, making it possible for peptide carriers to penetrate [30]. Javed *et al* (2016) used C2-9r ( $\text{H}_2\text{N}$ -CDIFTNSRGKRAGGGGrrrrrrrr, where r is D-arginine) to deliver siRNA for suppressing the  $\alpha$ -synuclein ( $\alpha$ -Syn) gene, implicated in the development of PD. CDIFTNSRGKRA is a shorter version of RVG, linked with four extra glycine acting as a spacer and positively charged arginine (R), which at the end of the C-terminus bind with negatively-charged siRNA. It was reported that this delivery system (peptide-based) not only crosses the BBB, but also stabilizes the siRNA that suppresses the  $\alpha$ -Syn protein, thus mitigating PD-like symptoms [31]. Although this delivery system has been derived from the rabies virus, it was reported to be non-toxic to neuronal cells.

Venom-derived, peptide-based shuttles have been reported to cross the BBB and to be able to deliver drugs to the desired site. Oller-Salvia *et al* (2016) have demonstrated that miniAp-4 (H-DapKAPETALD-NH<sub>2</sub>) derived from Apamin (a neurological toxin from bee venom) is able to cross the BBB and can deliver gold nanoparticles (NPs), showing proof of concept for drug delivery [32]. PepH3 (AGILKRW) has shown greater penetration upon i.v. administration in CD1 mice and bio-distribution was measured in mice sacrificed 5 min and 1 h after administration. Furthermore, its clearance and excretion is relatively fast, making it a good candidate for a shuttle carrier [33]. Spontaneous internalisation of nanowires (NW), linked with a cell penetrating peptide: the trans-activating transcriptional activator (TAT) from human immunodeficiency virus 1, has also been reported [34]. Two other shuttle peptides PWVPSWMPPRHT and GPVPSWMPPRHT (composed of D-amino acids) have been found to cross the BBB and are able to transport drug molecules or diagnostic substances into the CNS. These peptides have been reported to be biocompatible and non-toxic (as they were made up of amino acids) [35]. In recent decades, a number of BBB shuttle peptides with improved efficiency have been reported (table 1). Apolipoprotein (Apo) derivative peptides have been shown to cross the BBB (in *in vitro* and *in vivo* experiments) [36, 37]. Whilst numerous studies have demonstrated that Apolipoprotein B (ApoB) (SSVIDALQYKLEGTTTLTRKRLKLATLSLSNKFVEGS) and Apolipoprotein E (ApoE) (LRKLRL<sub>2</sub>) analogues are able to cross the BBB [38–40]. Gao *et al* (2012) reported the use PEG-(poly( $\epsilon$ -caprolactone)) NPs (prepared by emulsion solvent evaporation) for brain drug delivery, and contained docetaxel, a widely used drug in the treatment of several malignancies including brain tumours. They successfully conjugated a phage displayed TGN (table 1) peptide and an AS1411 aptamer, which specifically targets the ligands on the BBB and cancer cells respectively. *In vitro* experiments showed excellent permeability across the BBB along with suitable endothelial monolayer targeting. *In vivo* imaging showed that unmodified NPs hardly distributed in the brain



**Table 1.** A list of shuttle peptides that can target the BBB.

Peptide	Typical Sequence	Origin	Transport Mechanism	References
g7	GFtGPLS ( <i>O</i> - $\beta$ -d-glucose)CONH <sub>2</sub>	Enkephalin analogues/opioid	RMT	[48–51]
Apamin	H-CNCKAPETALCARRCQQH-NH <sub>2</sub>	Venom neurotoxin	Unknown	[32]
MiniAp-4	[Dap]KAPETALD	Venom neurotoxin	Unknown	[32]
Regulon polypeptides	PTVIHGKREVTLHL	Neurotropic endogenous Protein	LDLR	[52]
RAP	ELKHFEAKIEKHNHYQKQLE	Neurotropic endogenous Protein	LDLR	[52]
Angiopep-2	TFFYGGSRGKRNNFKTEEY	Neurotropic endogenous Protein	LRP1	[53, 54]
TAT (47-57)	GGGGYGRKKRRQRRR	HIV Protein	CD4 + T lymphocytes	[55]
PhPro	[Phenyl-Proline] <sub>4</sub>	Chiral library design	Passive transport (paracellular and transcellular)	[56]
RI-OR2-TAT	Ac-rGffvIkGrrrrqrkkkGy-NH <sub>2</sub>	HIV Protein and Amyloid beta	A $\beta$ peptide binding	[57]
SynB1	RGGRLSYSRRRFSTSTGR	Protegrins	AMT	[58]
Pep 22	Ac-[cMPRLRGC]c-NH <sub>2</sub>	Phage display (receptor)	LDLR	[59]
Leptin 30	YQQVLTSLPSQNVLQIANDLENLRDLLHLLC	Leptin	RMT	[60]
TGN	TGNYKALHPHNG	Phage display	Unknown	[61, 62]
CNG-QSH	(d-CGNHPHLAKYNGT) (d-QSHYRHISPAQVC)	Phage display	Unknown/A $\beta$ peptide binding	[63]
LNP	KKRTLRLKNDKRC	the nucleolar translocation signal sequence of the LIM Kinase 2 protein	Caveolae-mediated endocytosis and macropinocytosis	[64]
ApoE (157-167)	(LRKLRKRLR) <sub>2</sub>	Apolipoprotein E	LRP1	[38, 39, 65]
ApoB	SSVIDALQYKLEGTTTLTRKRLKLATLSLSNKFVEGS	Apolipoprotein B	LRP2	[40]
RVG-29	YTIWMPENPRPGTPCDIFTNSRGKRASNG	Rabies Virus Glycoprotein	nAChR	[30]
G23	HLNILSTLWKYRC	Phage display	GM1 and GT1b	[66, 67]
T7	HAIYPRH	Phage display	hTfR	[68–71]
THR	THRPPMWSPVWP	Phage display	hTfR	[35, 72–74]
THRre	pwvpswmprrht (retro-enantio version of THR)	Phage display	hTfR	
THRre_2f	(pwvpswmprrht) <sub>2</sub> KKGK(CF)G	Branched - Phage display	hTfR	[75]
DKP	Phe(p-NH-Dhp)-L-N-Me[Cha]/[2Na]	Unknown	Passive diffusion	[76]
GSH-PEG	GSH[PEG]	Endogenous tripeptide	Glutathione	[77–79]
CDX	D-[FKESWREARGTRIERG]	Structure-guided design	nAChR	[80, 81]
CRT	CRTIGPSVC	Phage display	TfR	[82]
T7 - #2077	RLSSVDSLSGC	Phage display	RMT	[83]
CAQK	CAQK	Phage display	Proteoglycan complex	[84]



while AsNPs (AS11411 conjugated NPs) accumulated slightly in the brain. However, the accumulation of TGN conjugated NPs in the brain significantly increased and the brain distribution achieved the highest intensity at 12 h [41]. GRN1005 a peptide-drug conjugate (taxane paclitaxel and angiopep-2 (ANG = TFFYGGSRGKRNNFKTEEY)) that interacts with lipoprotein receptor-related protein 1 (LRP1) has shown excellent permeability across the BBB. Phase I and II clinical trials suggested that GRN1005 was able to cross the BBB and limit tumour growth [42, 43]. Similarly, Li *et al* (2016) used a combination of two peptides (ANG and TAT) conjugated with paclitaxel to deliver the drug across the BBB [44]. Zou *et al* (2019) used a 16 lysine (K16) residue-linked low-density lipoprotein receptor-related protein (LDLR)-binding amino acid segment of apolipoprotein E (K16ApoE) to deliver a therapeutic peptide (HAYED) into an AD mouse model brain leading to reduced the necrosis [45]. Numerous shuttle peptides have been investigated for drug delivery to the brain but there is still a need to find magical combination. In another study, Sonoda *et al* (2018) formulated a BBB penetrant protein conjugate (JR-141), comprising an anti-human transferrin receptor (hTfR) antibody and human iduronate-2-sulfatase (hIDS) to treat mucopolysaccharidosis II (MPS II, caused by accumulation of glycosaminoglycans) [46]. Upon i.v. administration, JR-141 was detected in the brain but hIDS alone failed to penetrate into the brain. In addition, ostensibly therapeutic outcomes were observed, with a lower accumulation of glycosaminoglycans measured in brain and peripheral tissues [46]. Self-assembled peptide nanoligand derived from phage display library was used to down regulate the BACE1 without toxicity and inflammation [47].

Datta *et al* (2000) used a receptor binding domain peptide derived from human apolipoprotein E (hApoE), LRKLRLRL [hApoE (141–150)] as a vehicle to cross the BBB. They fused hApoE (141–150) with 18A (DWLKFYDKVAEKLKEAF) [Ac-He18a-NH<sub>2</sub>], a high affinity lipid-associated peptide to assess the uptake and degradation of low-density lipoprotein (LDL) in murine embryonic fibroblast (MEF1). In addition, four analogues were prepared, of which, Ac-LRRLRLRL-18A-NH<sub>2</sub> [Ac-hE(R)18A-NH<sub>2</sub>] and Ac-LRKMRLMR-18A-NH<sub>2</sub> (Ac-mE18A-NH<sub>2</sub>) have an extended hydrophobic moiety, including the receptor binding region. Control peptides were Ac-LRLLRLKRR-18A-NH<sub>2</sub> [Ac-hE(Sc)18A-NH<sub>2</sub>], which has amino acid residues of the ApoE to disrupt the hydrophobic face, and Ac-RRRRRRRR-18A-NH<sub>2</sub> (Ac-R1018A-NH<sub>2</sub>), which has only positively charged arginine (R) as the receptor binding domain. Increased internalisation of LDL was observed by 3-, 5- and 7-fold by Ac-mE18A-NH<sub>2</sub>, Ac-hE18A-NH<sub>2</sub>, and Ac-hE(R)18A-NH<sub>2</sub>, respectively, whereas the control peptides had no significant biological activity as illustrated in figure 3 [38]. Wang *et al* (2013) used a receptor binding peptide of ApoE (residues 159–167 [monomer: LAVYQAGAR], but the peptide had 18 amino acids, 2 × monomer) fused to IDUA (a lysosomal enzyme, α-L-iduronidase) [IDUAe1] to deliver across the BBB by targeting the LRP1, for the treatment of mucopolysaccharidosis (MPS) type I [39]. Zhang *et al* (2018) used BBB shuttle peptides to enhance the brain transduction of AAV8 after systemic administration. THR (THRPPMWSPVWP-NH<sub>2</sub>), a shuttle peptide that binds specifically to TfR1 was used to promote the internalization and transduction of AAV8 in a dose dependent manner [85].

## 4. Novel nanotechnology for brain drug delivery

NPs are carriers composed of natural (e.g. lipidic) or synthetic (e.g. polymeric) materials ranging from 1–500 nm in size. NPs are able to encapsulate, adsorb, or conjugate drugs or diagnostics and release the payload at a specific rate in the human body [86]. The physicochemical properties of NPs such as size, surface charge (zeta potential), morphology and composition are important factors deciding the fate of NPs, such as passage across the BBB, biological activity, release profile and biocompatibility [87]. A list of NPs used for brain drug delivery are summarised in table 2.

### 4.1. Polymeric NPs (PMNPs)

Polymeric NPs (PMNPs) are most extensively studied for the purpose of drug delivery. These NPs can not only deliver small drug molecules but can also be used for the delivery of genes and proteins [101]. PMNPs can have good penetration through cell membranes, serum stability, and can be easily manufactured. Furthermore, the surface of NPs can be modified for various medical applications. For brain drug delivery, PMNPs are made up of proteins, amino acids, polysaccharides and polyesters. Different mechanisms can be adapted by the PMNPs to cross the BBB. They can cross the BBB either by transcytosis through endothelial cells, mucoadhesion, or by disturbing the TJ in the brain capillaries [102]. On the other hand, PMNPs can be identified upon i.v. injection by the reticuloendothelial system (RES), leading to wide distribution to liver, spleen and bone marrow, resulting in elimination or very short half-lives [103]. Tf and poly-L-arginine (cell penetrating peptide) linked with 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) liposomes were developed for brain delivery of imaging agents and DNA [104]. B6 (CGHKAKGPRK), a TfR-specific peptide, and GE11 (CYHWYGYTPQNVI), a peptide specific for endothelial growth factor receptor (EGFR) overexpressed on cancer cells, were linked with poly(amido)amine-PEG (PAMAM-PEG) based dendriplexes for siRNA delivery [105].

PLGA-NPs modified with 7-amino acid glycopeptide (g7) have been shown to deliver small drug molecules across the BBB in rodents. Furthermore, g7-NPs successfully crossed the BBB with model drug (fluorescein isothiocyanate (FITC)-albumin). Injection in wild-type and knockout mice clearly showed penetration into the brain [88]. Luo *et al* (2017) developed high-intensity focused ultrasound (HIFU) responsive angiopep-2-decorated poly(lactic-co-glycolic acid) (PLGA) hybrid NPs able to transport doxorubicin/perfluorooctyl bromide (ANP-D/P). Decorated-NPs showed 17-fold increased accumulation in glioblastoma and 13.4 fold higher than unmodified NPs. Significant amount (47%) of drug released within two minutes after HIFU irradiation, causing apoptosis of tumour cells [106]. Methoxypolyethylene glycol (MPEG) and methoxypoly(ethylene glycol)-*b*-polycaprolactone (PCL) NPs, conjugated with angiopep-2 (CTFFYGGSRGKRNNFKTKRY) peptide with encapsulation efficiency of more than 95% showed higher *in vivo* accumulation in the brain [107].

Di Mauro *et al* (2018) developed novel biodegradable block co-polymeric NPs, functionalized with two different peptides AGBBB015F (CGGKTFFYGGSRGKRNNFKTEEY) and Regulon (HKKWQFNSPFVPRADPARKGKVHIPPFLDNITCRVPMAREPTVIHGKREVTLHLHPDH). These peptide functionalized NPs showed higher brain permeability than non-functionalized in U-87 MG cell line [108]. K16ApoE decorated PLGA-NPs have shown better accumulation in the cerebral vasculature. These NPs showed higher uptake into brain and provided better MRI contrast for diagnostic purpose [109].

### 4.2. Metallic NPs

Metallic NPs for brain delivery have been under investigation due to their serum stability and long half-life. Ghorbani *et al* (2018) reported the use of gold-iron nanocomposites encapsulated with curcumin-lipoic acid, a pH-sensitive delivery system for the brain. GSH is used as targeting ligand, leading to 2-fold increases in cellular uptake [110]. Nosrati *et al* (2019) reported the use for glutathione (GSH) decorated iron NPs (GSHIONPs) for brain drug delivery. IONPs@Asp-PTX-PEG-GSH are stable, non-toxic and enhance MRI contrast for diagnostic purpose [111].

In a comparative study conducted by Wang *et al* (2019) reported the peptide functionalized polyethylene glycol and maleic anhydride-coated superparamagnetic iron oxide nanoparticles (Mal-SPIONs) showed better diffusion to the thalamus, frontal cortex and temporal lobe than bovine serum albumin (BSA) conjugated NPs [112]. In another study, Albertini *et al* (2019) used AUNPs decorated with RGD like peptides (GRGDG-NH<sub>2</sub>, GRGDS) for drug delivery to brain tumour. Two hours after injection, the concentrations of NPs were 1.5 and 5 fold higher than undecorated NPs and PEGylated NPs [113]. TAT-conjugated gold NPs have been employed for brain drug delivery. The cellular uptake of AuNPs-TAT was 7.4% compared to 0.03% of AuNPs-PEG [114]. Chlorotoxin (CTX), a glioma specific peptide conjugated with polyethylenimine-entrapped gold nanoparticles (Au PENPs) showed excellent penetration into brain [115]. Ivask *et al* (2018) evaluated the uptake of iron oxide NPs conjugated with biomimetic phosphorylcholine brushes in an *in vitro* BBB model system. They reported



**Table 2.** A summary of formulations (NPs) targeting the BBB.

Formulation/Polymer	Drug	Disease	Method used for NP preparation	Mechanism for BBB crossing	Key findings	References
g7-PLGA-NPs (NPs of less than 300 nm)	FITC-albumin	MPS I and MPS II	Double emulsion technique	RMT	The C57BL/6 Idua knockout and C57BL/6 Ids knockout mice were used. High MW molecule delivery across the BBB achieved	[88]
Functionalized solid lipid NPs with apolipoprotein E, (SLN-DSPE-ApoE) (Average size was less than 200 nm with zeta potential of $-10$ – $15$ mV)	Resveratrol	Neuroprotective	High shear homogenization	LDLR	<i>In vitro</i> cytotoxicity evaluation via MTT and LDH using hCMEC/D3 cell line showed that SLNs affected neither the metabolic activity of the cells nor the membrane integrity at concentrations less than $1500 \mu\text{g ml}^{-1}$ . hCMEC/D3 monolayers in transwell devices showed SLN-DSPE-ApoE, permeabilities 1.5-fold higher than for non-functionalized SLNs	[89]
Bovine Serum Albumin NPs with LMWP cell penetrating peptide (LMWP-albumin) [LMWP: CVSRRRRRRGRRRR] (Particle size less than 200 nm,)	PTX and 4-HPR	Brain cancer	Self-assembly	Brain penetration mainly by EPR, but also through SPARC and gp60 albumin binding proteins overexpressed in glioma tissues	FACS showed <i>in vitro</i> cellular uptake of the NPs. bEnd.3 cell line showed BBB penetration of the NPs U87 cells showed cytotoxicity of NPs. The NPs were administered by i.v. injection to orthotopic glioma (Luc-U87) mouse model (bearing intracranial tumor). The mice received the NPs (LMWP-modified bovine serum albumin (BSA) NPs containing PTX and 4-HPR) showed the longest survival time	[90]
PEG-PLA-penetratin (RQIKIWFQNRRMKWKK) (Particle size 100 nm, zeta potential $-4.42$ mV)	Coumarin-6	CNS disorders	Emulsion/solvent evaporation technique	AMT/RMT	MDCK-MDR cell model showed enhanced accumulation via both lipid raft-mediated endocytosis and direct translocation. <i>In vivo</i> administration showed significant brain uptake with less deposition in non-target tissues	[91]

Table 2. (Continued.)

Formulation/Polymer	Drug	Disease	Method used for NP preparation	Mechanism for BBB crossing	Key findings	References
Angiopep conjugated with poly(ethylene glycol)-co-poly( $\epsilon$ -caprolactone): ANG-PEG–poly( $\epsilon$ -caprolactone) (Particle size was less than 100 nm with zeta potential of $3.28 \pm 0.75$ mV)	Paclitaxel	Glioblastoma multiforme	Sonication	LDLR	U87 MG glioma cells indicated the ANG-PEG- poly( $\epsilon$ -caprolactone) NPs uptake via LDLR (Angiopep-2 and Aprotinin significantly reduced the cellular uptake of the NPs). Real time fluorescence imaging showed accumulation of ANG-NPs in the brain of intracranial U87 MG glioma tumor-bearing nude mice after i.v. injection.	[92]
TAT-poly(ethylene glycol) (PEG)-b-cholesterol: TAT–PEG- <i>b</i> -Chol (Particle size less than 200 nm)	Ciprofloxacin	Encephalitis	Self-assembly	AMT	Enhanced <i>in vitro</i> cellular (ACBRI 376) uptake. NPs crossed the BBB and located around the cell nucleus of neurons (SD adult rats) following i. v. injection	[93]
RVG-29-PEG-PLGA/DTX-NPs (Particle size was around 110 nm)	Docetaxel	Gliomas	Nanoprecipitation	nAchR	<i>In vitro</i> bEnd3 cells showed permeability across the BBB. RVG-29-PEG-PLGA/DTX-NPs had a stronger inhibitory effect on C6 cell proliferation than free DTX. <i>In vivo</i> experiments confirmed selective accumulation of NPs in intracranial glioma tissues following i.v. injection.	[94]
PEG-Poly( $\epsilon$ -caprolactone)-CH <sub>2</sub> R <sub>4</sub> H <sub>2</sub> C/Stearate-CH <sub>2</sub> R <sub>4</sub> H <sub>2</sub> C (CH <sub>2</sub> R <sub>4</sub> H <sub>2</sub> C: CHHRRRRHHC peptide) (Particle size was in the range of 50–100 nm with zeta potential of 15–20 mV)	Dextran (as model drug)	CNS disorders	Self-assembly	Olfactory nerve channels	Hydrophobic carrier is more suitable for the delivery of drug in forebrain, while hydrophilic carrier is suitable for hindbrain (brainstem).	[95]
g7- PLGA- Np (Particle size was in the range of $155 \pm 26$ nm with zeta potential of $-15 \pm 5.6$ mV)	Loperamide	CNS disorders	Nanoprecipitation	AMT	Long term <i>in vitro</i> release over 192 h and 20% in 2 h. <i>In vivo</i> experiments showed excellent bio-distribution in brain.	[96, 97]
mPEG–PLGA-RVG (Particle size was in the range of $168.8 \pm 1.9$ nm with zeta potential of $-27.40 \pm 0.71$ mV)	Deferoxamine	PD	Double emulsion technique	nAchR	<i>In vivo</i> administration reduced the oxidative stress and iron contents in	[98]

Table 2. (Continued.)

Formulation/Polymer	Drug	Disease	Method used for NP preparation	Mechanism for BBB crossing	Key findings	References
siRNA/TMC-PEG-RVG (Particle size was in the range of $207 \pm 2$ nm with zeta potential of $9 \pm 2.5$ mV)	siRNA	AD	—	nAchR	the substantia nigra and striatum of PD mice. <i>In vitro</i> and <i>in vivo</i> experiment showed excellent penetration into brain with low toxicity and higher serum stability.	[99]
AuNCs-RDP (Particle size was in the range of $10 \pm 2.85$ nm with zeta potential of $-5.92 \pm 3.16$ mV)	Carboxyfluorescein	Neural cell imaging	Green synthetic route	RMT	<i>In vitro</i> and <i>in vivo</i> results suggested the effective internalization in the brain cells.	[100]

that after 24 h, 78% of the formulation crossed the BBB via adsorption mediated transport (AMT) [116]. This ability of iron oxide NPs has provided the opportunity of delivering therapeutic peptides to the brain by conjugating the peptide to the surface of iron-oxide NPs (5 nm diameter) [117]. Tf-conjugated magnetic dextran-spermine NPs (DS-NPs) have also demonstrated excellent penetration across the BBB [118].

Kang *et al* (2016) reported a single-step procedure to simultaneously load porous silicon NPs with high concentrations of siRNA and protecting them by formation of  $\text{Ca}_2\text{SiO}_4$  at the surface of NPs (pSiNPs). These core-shell NPs had the size of  $180 \pm 20$  nm. Then pSiNPs were surface functionalised with RVG peptide (cell targeting ligand) and a cell penetrating peptide (myr-GWTLNSAGYLLGKINLKALAALAKKIL(GGCC), a myristoylated transportan) to deliver the siRNA across the BBB. Addition of these peptides increased the size of pSiNPs to 220 nm. The pSiNPs were administered intravenously to mice with brain injury, and a significant amounts of siRNA were accumulated at the site of injury [119]. Similarly, Lee *et al* (2017) reported the use of rabies virus-mimetic silica-coated gold nanorods to treat brain gliomas. The nanorods were prepared by converting spherical gold NPs to gold nanorods. Then coating the gold nanorods with  $\text{SiO}_2$ . This was to adjust the size of the nanorods to the size of rabies virus as much as possible. This was followed by coating the resulting Au- $\text{SiO}_2$  nanorods by PEG and RVG-29. The nanorods (RVG-PEG-Au@ $\text{SiO}_2$ ) had the length of  $117.7 \pm 7.3$  nm and width of  $50.3 \pm 3.1$  nm. The RVG-PEG-Au@ $\text{SiO}_2$  nanorods were administered intravenously to orthotopic glioma-bearing mice, which *in vivo* fluorescence imaging indicated the accumulation of RVG-PEG-Au@ $\text{SiO}_2$  nanorods in the mouse brains. The mice were subjected to photothermal therapy using near infrared (NIR) laser. The temperature changes (up to  $60^\circ\text{C}$ ) caused by the laser therapy (localized surface plasmon resonance) of gold nanorods resulted in irreversible damages to or death of tumor cells. Tumor volumes in mice treated with RVG-PEG-AuNRs@ $\text{SiO}_2$  nanorods and applying NIR laser were considerably smaller than those of mice treated with PEG-AuNRs@ $\text{SiO}_2$  nanorods or control saline ( $124.8 \pm 147.5$ ,  $1067.4 \pm 295.4$ , and  $2323.2 \pm 436.3$  mm<sup>3</sup>, respectively) at 7 d after the treatment. Even, the tumors of two mice treated with RVG-PEG-AuNRs@ $\text{SiO}_2$  nanorods nearly vanished. This therapy caused slight skin damage by 808 nm laser irradiation, which was healed after 13 days [120]. This study indicates that even the EPR of the brain tumors was not sufficient to allow accumulation of PEG-AuNRs@ $\text{SiO}_2$  nanorods in the tumors and use of RVG-29 cell targeting peptide was necessary to achieve desired therapeutic outcomes. In addition, the size of RVG-PEG-AuNRs@ $\text{SiO}_2$  nanorods could be part of the successful application of these NPs.

Numerous factors control the systemic circulation, cell penetration and BBB passage of NPs. Particle size is one of the important factors controlling the access of NPs across the BBB. Studies conducted in animal models of AD, PD and stroke have used NPs of 50–100 nm [121–126]. Several techniques, such as dynamic light scattering (DLS), atomic force microscopy (AFM), TEM and scanning electron microscopy (SEM) are used to characterise NPs [127]. Several factors control the particle size, such as the polymers used, drug loading, drug/polymer ratio and hydrophilic/lipophilic ratio. Previous studies have reported an increase in particle size after drug loading [128, 129]. On the other hand, Lopalco *et al* (2015) have reported no changes in the size of NPs made up of PLGA, PLGA-d- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate (TGPS) and Resomer RGPd5055 pre- and post-loading of drugs (oxcarbazepine and coumarin-6) [130].

#### 4.3. Exosomes

Exosomes are comprised of natural lipid bilayers with an abundance of adhesive proteins that readily interact with cellular membranes. These are small extracellular nanovesicles secreted by numerous cell [131, 132]. Naturally-occurring extracellular vesicles such as exosomes traffic endogenous small molecules, proteins and nucleic acids between cells, [133, 134] and they have shown considerable promise for the delivery of exogenous drugs or biological therapeutics, [135–138] including to the brain [139, 140]. Exosomes have several advantages over synthetic NPs in that their biocompatibility confers upon them an inherent non-immunogenicity and long circulation times, however surface-functionalisation (e.g. for targeted delivery) and synthetic analogues of ‘natural’ exosomes have also proven to be successful therapeutic strategies [141–143]. Drugs delivered by means of an exosomal vector often show enhanced efficacy and fewer adverse effects. Enhancing and exploiting the innate drug-delivery capabilities of exosomes make for a highly attractive therapeutic approach.

Alvarez-Erviti *et al* (2011) used exosomes (obtained from self-derived dendritic cells) decorated to express Lysosome-associated membrane protein 2b (Lamp2b) and fused with neuron-specific RVG peptide to deliver siRNA into mouse brains [144]. They also compared the immune response of siRNA-RVG exosomes and siRNA-RVG-9R *in vivo* by measuring the interleukin (IL)–6, interferon gamma-induced protein (IP)–10, tumor necrosis factor (TNF)- $\alpha$  and interferon (IFN)- $\alpha$  serum levels. They found non-substantial changes in all cytokines compared to siRNA-RVG-9R [144]. Although, IFN- $\alpha$  and IP-10 increased in average for mice injected with siRNA-RVG exosomes compared to control mice [144].

Curcumin-loaded exosomes tagged with cyclo(Arg-Gly-Asp-D-Tyr-Lys) peptide [c(RGDyK)] were used to target the lesion region of the ischemic brain in a transient middle cerebral artery occlusion (tMCAO) mouse

model [145]. Alvarez-Erviti *et al* (2011) used RVG decorated exosomes to deliver siRNA to the mouse brain [144]. Long *et al* (2017) used A-1 exosomes (derived from human bone marrow mesenchymal stem/stromal cells (MSCs)) for the rectification of pilocarpine-induced status epilepticus (SE) [146]. Exo-JSI124 exosomes derived from EL-4 cells (a mouse lymphoma cell line) were used to deliver an encapsulated anti-inflammatory drug in experimental autoimmune encephalomyelitis (EAE) mice via an intranasal route, modulating inflammation [147]. Exosomes derived from dendritic cell cultures treated with interferon- $\gamma$  were found to increase myelination in rats upon intranasal administration, possibly by delivery of miR-219 [148]. Exosomes loaded with superparamagnetic iron oxide NPs (SPIONs) and curcumin and conjugated with neuroleptin-1-targeted peptide (RGERPRR) crossed the BBB and were used for imaging and treatment of glioma [149]. Iraci *et al* (2017) revealed the unexpected ability of stem cell exosomes to harbour and deliver functional enzymes (e.g. Asparaginase-like 1) extracellularly, thus behaving as fully independent small metabolic units with exciting therapeutic implications [150].

Cooper *et al* (2014) described the use of exosomes derived from murine bone marrow dendritic cells to block the aggregation of  $\alpha$ -Syn, a pathological process implicated in PD progression. siRNA-loaded exosomes decorated with RVG (targeting ligand) effectively reduced the  $\alpha$ -Syn aggregation in normal mice and transgenic mice expressing the human phosphorylation-mimic S129D  $\alpha$ -Syn [151]. Dopamine-loaded exosomes derived from the blood of mice were used to deliver drugs across the BBB with lower systemic toxicity compared to i.v. administration of naked dopamine [152]. As an alternative approach, Haney *et al* (2015) circumvented the BBB, using intranasal delivery to successfully administer the catalase-loaded macrophage-derived exosomes to the brain of mice with a model of PD, resulting in significant neuroprotective effects [131]. Conversely, a potential role of exosomes in diagnosing neurodegenerative conditions was highlighted by Gui *et al* (2015) who developed a microRNA-profiling strategy for the early detection of PD. They used exosomes isolated from the CSF of PD and AD patients, reporting sixteen miRNAs upregulated and 11 miRNAs under regulated in PD [153].

Liu *et al* (2015) successfully deployed exosomes expressing RVG on the surface loaded with opioid receptor mu (MOR) siRNA into the brain for the treatment of morphine addiction [154]. Wu *et al* (2018) also used RVG decorated exosomes for brain drug delivery. They encapsulated siRNA targeting human huntingtin exon 1 (HuHtt) transcript. HuHtt-siRNA loaded RVG-exosomes were then administered intravenously to normal mice and BACHD and N171–82Q transgenic (Huntington's Disease-model) mice at  $10 \text{ mg kg}^{-1}$  every two days for 2 weeks. siRNA-loaded RVG exosomes significantly reduced HuHtt mRNA and protein levels up to 46% and 54%, respectively, in transgenic animals [155].


#### 4.4. Liposomes for brain drug delivery

Liposomes are self-assembled NPs made up of phospholipid bilayer membrane. Phospholipids are heterogeneous molecules containing phosphate residues, polar head groups, and non-polar alkyl chains [156] that self-assemble (according to the fluid mosaic model) into biological membranes. Liposomes for brain drug delivery have been studied extensively in the last two decades.

Pulford *et al* (2010) formulated liposomes ( $178 \pm 20 \text{ nm}$ ) containing cationic lipid octadecenyl-3-hydroxyethyl imidazolium chloride to deliver siRNA into the brain of mice following i.v. injection. The cationic liposome-siRNA-peptide (RVG-9r) penetrates the BBB, with the peptide moiety binding to nAChRs [157]. Bender *et al* (2016) used two liposomal systems for the delivery of prion protein siRNA to the brain of mice following i.v. injection. One of the liposome formulations was cationic liposomes containing 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), which formed a complex with siRNA and RVG peptide. The other liposomal system contained DOTAP or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) to encapsulate the siRNA. Both systems decreased the prion protein expression of neurons in the CNS [158]. Grinberg *et al* (2005) reported novel cationic amphiphilic compounds synthesised from vernonia oil. The quaternary methyl ester derivative of methyl vernolate self-assembled into vesicles (in the presence of cholesterol 1:1) with the size of 50–200 nm in diameter [159]. Vesicles made from the quaternary vernonia oil derivative (triple-headed amphiphile) were found to be efficient in transfection of cDNA encoding for GFP into cultured COS-7 cells [159]. These vesicles were employed to deliver analgesic peptides (kyotorphin or leu-enkephalin) to the brain of male ICR mice following i.v. injection [160].

Moreover, Conceicao *et al* (2016) reported that the RVG-9r peptide decorated liposomes (also referred as stable nucleic acid lipid particles [SNALPs]) were able to cross the BBB and deliver siRNA, which can target mutant ataxin-3 in the brain of Machado-Joseph disease mouse models. These SNALPs offered high encapsulation of siRNA, optimum particle size and almost no toxicity. *In vivo* experiments showed the ability of SNALPs to accumulate in the brain and silence the mutant ataxin-3 upon i.v. injection as shown in figure 4 [161].





#### 4.5. Dendrimers for brain drug delivery


Dendrimers are chemically synthesised polymeric particles with defined shapes (due to monodispersity). Dendrimers have been investigated for brain drug delivery. It has been reported, apolipoprotein A-I (ApoA-I) and NL4-peptide dual modified dendrimer NPs were efficient carriers for siRNA delivery to PC12 cells and efficiently penetrate through a bEnd.3 monolayer via LDLR [162]. KE *et al* (2009) used PAMAM-PEG-Angiopep/DNA-NPs to deliver plasmid DNA across the BBB. The PAMAM was fifth generation with 128 surface primary amino groups. *In vitro* BBB model showed clathrin and caveolae-mediated endocytosis (also partly through macropinocytosis) of the nanocarriers containing Angiopep peptide [TFFYGGSRGKRNNFKTEEYC]. PAMAM-PEG-Angiopep dendrimers were loaded with pEGFP plasmid; and the NPs were administered intravenously to mice. Gene expression was observed in all four regions of the mouse brain for the PAMAM-PEG-Angiopep/DNA NPs, which was much higher than those for the PAMAM/DNA NPs [163]. In another study, low generation lysine dendrons (G0 and G1) conjugated with ApoE derived peptide (LRKLRKLLR) were reported to cross the BBB efficiently with no cytotoxicity up to 400  $\mu\text{m}$  [164]. It should be noted that PAMAM/siRNA complexes appear to show significant cell toxicity even at low concentrations such as 20  $\mu\text{g ml}^{-1}$  [165]. As it would be expected, the cationic dendrimers show haemolytic activity. However, increasing the dendrimer generation decreases the haemolytic activity. For example, G2 dendrimers showed 100% haemolysis at 1  $\text{mg ml}^{-1}$  concentration after 24 h incubation with RBCs, while G5 dendrimers showed no haemolysis (comparable to negative control) at the same concentration and incubation period [166]. Dynamic light scattering (DLS) studies showed that PAMAM/siRNA complexes had sizes in the range of 150–200 nm, while TEM results indicated a wider size distribution with majority in the range of 30–45 nm for G7 PAMAM/siRNA with N/P ratio of 10 [167].

#### 4.6. Carbon nanotubes

Carbon nanotubes (CNT) are cylindrical molecules that consist of rolled-up sheets of single-layer carbon atoms. Distinctive properties of CNT such as good electronic properties, excellent penetration into cell membrane, high loading capacity, pH-dependent unloading, greater surface area and ease of modification make them one of the suitable drug delivery system for the brain [168, 169]. CNT have been extensively investigated as a drug carrier to the brain in past few years. Functionalized CNT can potentially be used as a carrier for drugs that have poor permeability across the BBB and also can be used for diagnostic and for the treatment of brain disorders [170].

CNT can be synthesized electric arc discharge and laser ablation using vaporisation of graphite target [171] or by chemical vapour deposition [172]. CNT can be grouped into single wall carbon nanotubes (SWCNT) or multi wall carbon nanotubes (MWCNT) depending on the number of layers that constitute a CNT. CNT size ranges from 0.4 nm to 100 nm depending on the layers. CNT can be functionalized covalently or non-covalently [173].

Ren *et al* (2012) developed PEGylated oxidized multi-walled carbon nanotubes (O-MWNTs) modified with angiopep-2 (O-MWNTs-PEG-ANG) to treat brain glioma. They reported the high uptake and accumulation of CNT in the desired area with excellent loading capacity. Angiopep-2 specifically binds to LDLR and promotes the internalization. Doxorubicin loaded CNT were found to have better anti-glioma effects than naked doxorubicin [174]. In another study, ANG functionalized radiolabelled CNT were employed to deliver drug



**Figure 5.** Different morphologies and shapes of NPs used for brain drug delivery.

across the BBB. *In vitro* experiments suggested higher penetration of ANG-CNT than chemically functionalized CNT. Enhanced localization of ANG-CNT was reported upon *in vivo* injection and 2% of the injected dose was accumulated in the brain within the first hour post-injection [175, 176]. TAT (YGRKKRRQRRR) conjugated CNT were reported to have excellent BBB penetration and anticancer activity through increased ROS production [177].

#### 4.7. Parameters affecting the BBB transport

##### 4.7.1. Size, morphology and surface zeta potential

NPs in the range of 120–180 nm after crossing the BBB may be entrapped in the BL [178]. However, NPs with the size in the range of 16–24 nm are able to diffuse in the brain parenchyma [178]. These observations indicate that NPs should be less than 120 nm such as exosomes in order to diffuse in the brain parenchyma, otherwise they will remain trapped in the BL following crossing the BBB.

The morphology of NPs affects their bio-distribution and cellular uptake. NPs could be spherical, cubic, tubular or rod-like in shape [179, 180]. A majority of the particles reported for brain delivery are roughly spherical in shape. Zeta potential or surface charge of NPs is another factor that controls the diffusion across the BBB. It has been reported that a high (positive) zeta potential causes toxicity to the BBB [181, 182]. Rassu *et al* (2017) reported that a positive surface charge on NPs ensures their mucoadhesion [183]. On the other hand, NP formulations have been reported for brain delivery with zeta potentials between  $-1$  and  $-45$  mV [184–186]. Different shapes of NPs are shown in figure 5.

##### 4.7.2. Critical micelle concentration (CMC)

CMC is the minimum concentration of a compound at which it forms micelles. CMC plays a major role in the stability of micelles/NPs due to excessive dilution in the blood, upon i.v. injection. If the concentration in systemic circulation drops below the CMC, then it releases the payload in the blood stream before getting to its target.

CMC can be determined by using set concentrations of a pyrene probe with serial dilution of copolymer solution [187, 188]. Ruan *et al* (2018) used RAP12 peptide (a part of the receptor associated protein that binds to LRP1) and decorated PEG-poly(lactic acid) (PLA) micelles to deliver drug (paclitaxel) across the BBB [189]. Liu *et al* (2009) reported CG<sub>3</sub>R<sub>6</sub>TAT (CGGGRRRRRRYGRKKRRQRRR), a self-assembled cationic antimicrobial peptide able to cross the BBB. They measured the CMC by using the pyrene as a probe and found to be  $31.6 \text{ mg l}^{-1}$  ( $10.1 \text{ } \mu\text{m}$ ) in deionized water [187]. Micelles and PMNPs both can target the brain and cross the BBB. Efficacy and efficiency of crossing the BBB are dependent on targeting via the surface of the nanocarriers.

##### 4.7.3. Protein corona

NPs, upon contact with biological fluids, are surrounded by a protein layer that is called protein corona [190–193]. The first layer of protein corona is bound tightly on the surface (primary contact with NPs), which is referred as ‘hard’ corona. Usually, another layer is loosely bound on the first layer, which is referred as ‘soft’ corona; and that consists of serum proteins, mainly comprising albumin and its derivatives [194–196]. This surface adsorption of protein can alter the physiological response [195]. The adsorption of proteins on NPs mostly has undesirable effects such as prompt clearance from blood stream, compromised targeting capacity [197] and toxicity [198, 199]. Proteins bound to a NP surface may rearrange their structure and shape according

to NP surface and environment, this is known as ‘conformational change’. Conformational change accompanied with the modification of secondary or tertiary protein structure. Proteins are supposed to interact with other biomolecules to initiate biological responses, hence a small modification in protein structure has huge impact on their pharmacological activities [200].

Several factors dictate the nature of adsorbed proteins. Particle size plays an important role in protein adsorption. As NPs are bigger than proteins, NPs make proteins to adapt the NPs’ surface. Smaller NPs has less interaction with proteins [201]. Surface charge of the NPs affects the secondary structure of proteins. Huhn *et al* (2014) reported that gold NPs with different surface charge (positive [ $+9.7 \pm 8.9$  mV] or negative [ $-39.8 \pm 10.0$  mV]), but similar sizes adsorbed comparable amounts of HSA. Whereas, positively charged NPs showed higher cellular uptake than negatively charged NPs. This change in the activity can be due to conformation changes in protein structure due to surface charge [202]. Fleischer and Payne (2014) observed that similar NPs with identical protein corona compositions bind to different cellular receptors, suggesting that a difference in the structure of the adsorbed protein may be responsible for the differences in cellular binding of the protein–NP complexes. These authors also found that cationic polystyrene NPs showed improved cellular binding to monkey kidney epithelial cells compared to negatively charged NPs in the presence of fetal bovine serum (FBS). It should be noted that in both cases, the NPs formed protein–NP complexes immediately following exposure to FBS [199].

Media composition affects the protein corona. Silica NPs in the presence of serum proteins showed less uptake compared to serum free media [203]. Gold NPs incubated with Dulbecco’s Modified Eagle’s Medium (DMEM) media for 48 h showed higher protein adsorption than Roswell Park Memorial Institute media (RPMI), but same amount after 1 h incubation [204]. Protein concentration in media affects the protein corona. Silica NPs incubated with 3%, 20% and 80% plasma exhibited different protein patterns. Changes in primary protein band was observed with increasing plasma concentration. Lower amounts of proteins were measured on silica NPs compared to sulfonated polystyrene (PSO<sub>3</sub>) NPs with increased plasma concentrations [205]. Exposure time affects the protein corona. Protein corona forms immediately as soon as the NPs come into contact with human plasma. Tenzer *et al* (2013) reported complex protein corona (formed of 300 proteins) just after 30 s [206]. In addition, temperature plays an important role in protein corona formation. Cu-NPs showed higher protein adsorption when incubated by increasing temperature from 15 °C, 27 °C, and 37 °C to 42 °C [207].

A decline (from 76% to 26%) in the cellular uptake of cRGD decorated NPs was reported by Su *et al* (2018) in protein bound NPs compared to non-protein bound NPs. They found that even the targeting ability was not affected but cellular uptake was compromised [208]. Tf decorated NPs were reported to lose their targeting ability in the biological medium. Proteins in the medium are reported to shield the NPs and hence results in disappearance of targeting ability. However NPs can enter the cells but the targeting capacity is lost [209]. Aptamer functionalized AuNPs lost the targeting ability due to protein corona blocking after serum exposure. Immune related proteins were found on the surface of aptamer that can induce immune reaction and clearance eventually [210].

#### 4.7.4. Stability of NPs

The stability of NPs can be categorised into two, shelf stability and serum stability. NPs should be stable enough to retain their therapeutic effects for a specific time when stored or administered to the body. Oller-Salvia *et al* (2016) tested the serum stability of peptide NPs in human serum. They found that switching from linear to monocyclic analogue didn’t affect the permeability but showed 30-fold enhanced stability than linear peptide analogue [32]. In addition, upon switching disulphide to a lactam bridge in Miniap-4 shuttle peptide, they found 50% higher permeability with better resistance to proteases [32]. El-Marakby *et al* (2017) assessed the serum stability of chitosan NPs in rat serum. They reported a sharp reduction in particle size (up to 62% of original size) prepared from the native chitosan, whereas modified chitosan showed slight increase in the size from  $87.39 \pm 1.56$  nm to  $122.33 \pm 1.95$  nm after 2 h incubation with the serum. After 24 h incubation no significant changes were noticed [211]. Oliveira *et al* (2017), tested uncoated and poly allylamine hydrochloride (PAH)-coated PLGA-NPs in biological environments: BSA solution, mouse and human plasma. Both formulations were reported stable in BSA and mouse plasma on incubation, but surprisingly not stable in human plasma (formed aggregates greater than 1  $\mu$ m). They also studied protein corona in all solutions. In mouse plasma uncoated NPs showed protein concentration of  $4.1 \pm 2.6$   $\mu$ g ml<sup>-1</sup>, which was much greater than incubating these NPs in BSA solution. Surprisingly, in human plasma it was 2.5-fold higher ( $10.4 \pm 3.0$   $\mu$ g ml<sup>-1</sup>) than mouse plasma. Similarly PAH-coated PLGA-NPs showed higher protein adsorption after incubation with human plasma than BSA solution and mouse plasma [212].

Uncoated chitosan NPs were to increase in size by storage at 25 °C for 3 m in 10% glucose solution [213]. This alteration in size results in modified physicochemical, pharmacodynamic and pharmacokinetic properties of the PMNPs. Lyophilisation with cryoprotectants is reported to enhance the stability and to stop contents

leaking from the NPs [214–216]. Cryoprotectants such as glucose, sucrose, mannitol and trehalose are most commonly used because of their low toxicity [214, 217].

## 5. Conclusion

Peptide based drug delivery systems have been studied extensively in the last two decades to overcome the BBB. Peptide based formulations come with its advantages (less toxicity, low alteration in the BBB integrity and specific targeting) and disadvantages (serum stability). Shuttle peptides, exosomes, liposomes, NPs and dendrimers decorated with peptides have shown much improved permeability across the BBB. Targeting and crossing the BBB is an ever expanding and challenging yet promising field. To design and develop a CNS drug that can target the BBB requires a detailed understanding of both the BBB at a molecular level and drug properties (pharmacokinetics and pharmacodynamics). Despite many advances in drug delivery systems, there is still an essential need for research aimed at attaining improved delivery systems with fewer limitations. Peptide based delivery systems along with pro and cons need further optimization and high specificity in brain targeting.

## 6. Future direction

Despite extensive research in the use of peptides in nanoparticles for drug delivery to the brain, yet there is no clinical trial of them. Then, the next steps would be developing scalable and reproducible brain targeting nanoparticle delivery system using peptides as targeting ligands. Peptide based NPs provide the opportunity of formulating enzyme responsive or biodegradable delivery systems, which may offer less toxicity and immunogenicity, and improved efficacy. Peptide based nanoparticles should be able to deliver/encapsulate suitable amounts of drug to the brain; and these should protect the drug from enzymes in the blood.

## Conflict of interest

The authors declare no conflict of interest.

## ORCID iDs

Touraj Ehtezazi  <https://orcid.org/0000-0002-1576-2396>

## References

- [1] Steward M M, Sridhar A and Meyer J S 2013 Neural Regeneration ed E Heber-Katz and D L Stocum *New Perspectives in Regeneration*. (Berlin, Heidelberg: Springer Berlin Heidelberg) pp 163–91
- [2] Mahar M and Cavalli V 2018 Intrinsic mechanisms of neuronal axon regeneration *Nat. Rev. Neurosci.* **19** 323–37
- [3] Chekani F, Bali V and Aparasu R R 2016 Quality of life of patients with Parkinson's disease and neurodegenerative dementia: a nationally representative study *Research in Social and Administrative Pharmacy*. **12** 604–13
- [4] Josephs K A, Ahlskog J E, Parisi J E, Boeve B F, Crum B A, Giannini C and Petersen R C 2009 Rapidly progressive neurodegenerative dementias *Arch. Neurol.* **66** 201–7
- [5] Organization WH Neurological disorders affect millions globally: WHO report 2007 [cited 2018 06/08/2018]. Available from: (<http://who.int/mediacentre/news/releases/2007/pr04/en/>) ISBN 978 92 4 156336 9
- [6] Wenborn J et al 2016 Community occupational therapy for people with dementia and family carers (COTiD-UK) versus treatment as usual (Valuing Active Life in Dementia [VALID] programme): study protocol for a randomised controlled trial *Trials*. **17** 65
- [7] Gooch C L, Pracht E and Borenstein A R 2017 The burden of neurological disease in the United States: a summary report and call to action *Ann. Neurol.* **81** 479–84
- [8] Prince M, Wimo A, Guerchet M, Ali G, Wu Y and Prina M 2015 World Alzheimer Report, 2015 The global impact of dementia: an analysis of prevalence, incidence, cost and trends. *alzheimer's disease international (ADI)*
- [9] Cummings J, Aisen P S, DuBois B, Frölich L, Jack C R, Jones R W, Morris J C, Raskin J, Dowsett S A and Scheltens P 2016 Drug development in Alzheimer's disease: the path to 2025 *Alzheimer's Research & Therapy*. **8** 39
- [10] Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C and Fratiglioni L 2011 Cost of disorders of the brain in Europe 2010 *European Neuropsychopharmacology*. **21** 718–79
- [11] Georgieff M K 2007 Nutrition and the developing brain: nutrient priorities and measurement *The American Journal of Clinical Nutrition*. **85** 614S–20SS
- [12] Pardridge W M 2005 The blood-brain barrier: bottleneck in brain drug development *NeuroRx*. **2** 3–14
- [13] Gururangan S and Friedman H S 2002 Innovations in design and delivery of chemotherapy for brain tumors *Neuroimaging Clinics of North America*. **12** 583–97
- [14] Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L and Bernardino L 2016 Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases *J. Controlled Release* **235** 34–47
- [15] Rip J, Schenk G and De Boer A 2009 Differential receptor-mediated drug targeting to the diseased brain *Expert Opinion on Drug Delivery*. **6** 227–37



- [16] Treat L H, McDannold N, Zhang Y, Vykhodtseva N and Hynynen K 2012 Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma *Ultrasound Med. Biol.* **38** 1716–25
- [17] Pardridge W M 2001 BBB-Genomics: creating new openings for brain-drug targeting *Drug Discov Today*. **6** 381–3
- [18] Potjewyd G, Moxon S, Wang T, Domingos M and Hooper N M 2018 tissue engineering 3d neurovascular units: a biomaterials and bioprinting perspective *Trends Biotechnol.* **36** 457–72
- [19] Hawkins B T and Egleton R D 2007 Pathophysiology of the blood–brain barrier: animal models and methods *Current Topics in Developmental Biology*. **80** 277–309
- [20] Winkler E A, Bell R D and Zlokovic B V 2011 Central nervous system pericytes in health and disease *Nat. Neurosci.* **14** 1398–405
- [21] Sweeney M D, Ayyadurai S and Zlokovic B V 2016 Pericytes of the neurovascular unit: key functions and signaling pathways *Nat. Neurosci.* **19** 771
- [22] Golden P L and Pollack G M 2003 Blood–brain barrier efflux transport *J. Pharm. Sci.* **92** 1739–53
- [23] Abbott N J and Romero I A 1996 Transporting therapeutics across the blood–brain barrier *Molecular Medicine Today*. **2** 106–13
- [24] Abbott N J, Rönnebeck L and Hansson E 2006 Astrocyte–endothelial interactions at the blood–brain barrier *Nat. Rev. Neurosci.* **7** 41–53
- [25] Lipinski C A 2000 Drug-like properties and the causes of poor solubility and poor permeability *J. Pharmacol. Toxicol. Methods* **44** 235–49
- [26] Pajouhesh H and Lenz G R 2005 Medicinal chemical properties of successful central nervous system drugs *NeuroRx: the Journal of the American Society for Experimental NeuroTherapeutics*. **2** 541–53
- [27] Lipinski C A, Lombardo F, Dominy B W and Feeney P J 2001 Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings IPII of original article: S0169-409X(96)00423-1 The article was originally published in *Advanced Drug Delivery Reviews* 23 (1997) 3–25.1 *Advanced Drug Delivery Reviews*. **46** 3–26
- [28] Pardridge W M 2012 Drug transport across the blood–brain barrier *Journal of Cerebral Blood Flow & Metabolism*. **32** 1959–72
- [29] Pardridge W M 1986 Receptor-mediated peptide transport through the blood–brain barrier *Endocrine reviews*. **7** 314–30
- [30] Kumar P, Wu H, McBride J L, Jung K-E, Hee Kim M, Davidson B L, Kyung Lee S, Shankar P and Manjunath N 2007 Transvascular delivery of small interfering RNA to the central nervous system *Nature* **448** 39
- [31] Javed H et al 2016 Development of nonviral vectors targeting the brain as a therapeutic approach for parkinson's disease and other brain disorders *Molecular Therapy: the Journal of the American Society of Gene Therapy*. **24** 746–58
- [32] Oller-Salvia B, Sánchez-Navarro M, Ciudad S, Guiu M, Arranz-Gibert P, García C, Gomis R R, Cecchelli R, García J and Giralte E 2016 MiniAp-4: A Venom-inspired peptidomimetic for brain delivery *Angew. Chem.* **128** 582–5
- [33] Neves V et al 2017 Novel peptides derived from dengue virus capsid protein translocate reversibly the blood–brain barrier through a receptor-free mechanism *ACS Chem. Biol.* **12** 1257–68
- [34] Lee J-H, Zhang A, You S S and Lieber C M 2016 Spontaneous internalization of cell penetrating peptide-modified nanowires into primary neurons *Nano Lett.* **16** 1509–13
- [35] Prades R et al 2015 Applying the retro-enantio approach to obtain a peptide capable of overcoming the blood–brain barrier *Angew. Chem. Int. Ed.* **54** 3967–72
- [36] Zandl-Lang M et al 2018 Regulatory effects of simvastatin and apoJ on APP processing and amyloid- $\beta$  clearance in blood-brain barrier endothelial cells *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*. **1863** 40–60
- [37] Li X et al 2018 Apolipoprotein E-mimetic peptide COG1410 promotes autophagy by phosphorylating GSK-3 $\beta$  in early brain injury following experimental subarachnoid hemorrhage *Frontiers in Neuroscience*. **12** 127
- [38] Datta G, Chaddha M, Garber D W, Chung B H, Tytler E M, Dashti N, Bradley W A, Gianturco S H and Anantharamaiah G M 2000 The receptor binding domain of apolipoprotein E, linked to a model class a amphipathic helix, enhances internalization and degradation of LDL by fibroblasts *Biochemistry*. **39** 213–20
- [39] Wang D, El-Amouri S S, Dai M, Kuan C-Y, Hui D Y, Brady R O and Pan D 2013 Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier *PNAS* **110** 2999–3004
- [40] Spencer B J and Verma I M 2007 Targeted delivery of proteins across the blood–brain barrier *PNAS* **104** 7594–9
- [41] Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, Fan L, Xi Z, Jiang X and Zhang Q 2012 Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles *Biomaterials* **33** 5115–23
- [42] Drappatz J et al 2013 Phase I Study of GRN1005 in recurrent malignant Glioma *Clinical Cancer Research*. **19** 1567–76
- [43] Tang S-C et al 2016 ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study *Annals of Oncology*. **27** vi103
- [44] Li Y, Zheng X, Gong M and Zhang J 2016 Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma *Oncotarget*. **7** 79401–7
- [45] Zou Z et al 2019 The synthesized transporter K16APoE enabled the therapeutic HAYED peptide to cross the blood-brain barrier and remove excess iron and radicals in the brain, thus easing Alzheimer's disease *Drug Deliv. Transl. Res.* **9** 394–403
- [46] Sonoda H, Morimoto H, Yoden E, Koshimura Y, Kinoshita M, Golovina G, Takagi H, Yamamoto R, Minami K and Mizoguchi A 2018 A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis: II *Molecular Therapy*. **26** 1366–74
- [47] Wu L-P, Ahmadvand D, Su J, Hall A, Tan X, Farhangrazi Z S and Moghimi S M 2019 Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide *Nat. Commun.* **10** 4635
- [48] Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli M A and Forni F 2005 Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier *J. Controlled Release* **108** 84–96
- [49] Elmagbari N O et al 2004 Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides *J. Pharmacol. Exp. Ther.* **311** 290–7
- [50] Vilella A, Tosi G, Grabrucker A M, Ruozi B, Belletti D, Vandelli M A, Boeckers T M, Forni F and Zoli M 2014 Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution *J. Controlled Release* **174** 195–201
- [51] Tosi G et al 2011 NIR-labeled nanoparticles engineered for brain targeting: *in vivo* optical imaging application and fluorescent microscopy evidences *J. Neural Transm.* **118** 145–53
- [52] Borros G S, Rivero M F X and Cascante C A 2014 Google Patents; WO2014076655A1 Polypeptides for blood brain barrier transport (<https://patents.google.com/paten6133t/WO2014076655A1/fi>)
- [53] Demeule M, Régina A, Ché C, Poirier J, Nguyen T, Gabathuler R, Castaigne J-P and Béliveau R 2008 Identification and design of peptides as a new drug delivery system for the brain *J. Pharmacol. Exp. Ther.* **324** 1064–72
- [54] Bertrand Y et al 2010 Transport characteristics of a novel peptide platform for CNS therapeutics *Journal of Cellular and Molecular Medicine*. **14** 2827–39



- [55] Schwarze S R, Ho A, Vocero-Akbani A and Dowdy S F 1999 *In vivo* protein transduction: delivery of a biologically active protein into the mouse *Science* **285** 1569–72
- [56] Arranz-Gibert P, Guixé B, Malakoutikhah M, Muttenthaler M, Guzmán F, Teixidó M and Giralte E 2015 Lipid bilayer crossing—the gate of symmetry. water-soluble phenylproline-based blood-brain barrier shuttles *JACS* **137** 7357–64
- [57] Gregori M *et al* 2017 Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's A $\beta$  peptide *Nanomed. Nanotechnol. Biol. Med.* **13** 723–32
- [58] Drin G, Cottin S, Blanc E, Rees A R and Tamsamani J 2003 Studies on the internalization mechanism of cationic cell-penetrating peptides *J. Biol. Chem.* **278** 31192–201
- [59] Malcor J-D *et al* 2012 Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting *J. Med. Chem.* **55** 2227–41
- [60] Liu Y, Li J, Shao K, Huang R, Ye L, Lou J and Jiang C 2010 A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery *Biomaterials* **31** 5246–57
- [61] Zhang C, Wan X, Zheng X, Shao X, Liu Q, Zhang Q and Qian Y 2014 Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice *Biomaterials* **35** 456–65
- [62] Li J *et al* 2011 Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides *Biomaterials* **32** 4943–50
- [63] Zheng X, Pang X, Yang P, Wan X, Wei Y, Guo Q, Zhang Q and Jiang X 2017 A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer's disease mice *Acta Biomater.* **49** 388–401
- [64] Yao H, Wang K, Wang Y, Wang S, Li J, Lou J, Ye L, Yan X, Lu W and Huang R 2015 Enhanced blood-brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system *Biomaterials* **37** 345–52
- [65] Böckenhoff A, Cramer S, Wölte P, Knieling S, Wohlenberg C, Giesemann V, Galla H-J and Matzner U 2014 Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulphatase A *The Journal of Neuroscience*. **34** 3122
- [66] Georgieva J V, Brinkhuis R P, Stojanov K, Weijers C A G M, Zuilhof H, Rutjes F P J T, Hoekstra D, van Hest J C M and Zuhorn I S 2012 Peptide-mediated blood-brain barrier transport of polymersomes *Angew. Chem. Int. Ed.* **51** 8339–42
- [67] Zhang Y, Zhang W, Johnston A H, Newman T A, Pykkö I and Zou J 2012 Targeted delivery of Tet1 peptide functionalized polymersomes to the rat cochlear nerve *Int. J. Nanomed.* **7** 1015–22
- [68] Lee J H, Engler J A, Collawn J F and Moore B A 2001 Receptor mediated uptake of peptides that bind the human transferrin receptor *Eur. J. Biochem.* **268** 2004–12
- [69] Han L, Huang R, Liu S, Huang S and Jiang C 2010 Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors *Mol. Pharmaceutics* **7** 2156–65
- [70] Xie Y, Killinger B, Moszczynska A and Merkel O 2016 Targeted delivery of siRNA to transferrin receptor overexpressing tumor cells via peptide modified polyethylenimine *Molecules*. **21** 1334
- [71] Wang Z, Zhao Y, Jiang Y, Lv W, Wu L, Wang B, Lv L, Xu Q and Xin H 2015 Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system *Sci. Rep.* **5** 12651
- [72] Lledó E G, Turà M T and Cosano R P 2016 Google Patents; US20150044140A1 Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs (<https://patents.google.com/patent/US20150044140>)
- [73] Arranz-Gibert P, Ciudad S, Seco J, García J, Giralte E and Teixidó M 2018 Immunosilencing peptides by stereochemical inversion and sequence reversal: retro-D-peptides *Sci. Rep.* **8** 6446
- [74] Prades R *et al* 2012 Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor *Biomaterials* **33** 7194–205
- [75] Díaz-Perlas C, Oller-Salvia B, Sánchez-Navarro M, Teixidó M and Giralte E 2018 Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood-brain barrier transport *Chem. Sci.* **9** 8409–15
- [76] Teixidó M, Zurita E, Mendieta L, Oller-Salvia B, Prades R, Tarragó T and Giralte E 2013 Dual system for the central nervous system targeting and blood-brain barrier transport of a selective prolyl oligopeptidase inhibitor *Pept. Sci.* **100** 662–74
- [77] Lindqvist A, Rip J, Gaillard P J, Björkman S and Hammarlund-Udenaes M 2013 Enhanced brain delivery of the opioid peptide DAMGO in Glutathione PEGylated liposomes: a microdialysis study *Mol. Pharmaceutics* **10** 1533–41
- [78] Rotman M *et al* 2015 Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease *J. Controlled Release* **203** 40–50
- [79] Gaillard P J, Appeldoorn C C M, Rip J, Dorland R, van der Pol S M A, Kooij G, de Vries H E and Reijerkerk A 2012 Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation *J. Controlled Release* **164** 364–9
- [80] Wei X, Zhan C, Shen Q, Fu W, Xie C, Gao J, Peng C, Zheng P and Lu W A D 2015 Peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery *Angew. Chem. Int. Ed.* **54** 3023–7
- [81] Zhan C, Li B, Hu L, Wei X, Feng L, Fu W and Lu W 2011 Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand *Angew. Chem. Int. Ed.* **50** 5482–5
- [82] Staquicini F I *et al* 2011 Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma *The Journal of Clinical Investigation*. **121** 161–73
- [83] Urich E *et al* 2015 Cargo delivery into the brain by *in vivo* identified transport peptides *Sci. Rep.* **5** 14104
- [84] Mann A P *et al* 2016 A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries *Nat. Commun.* **7** 11980
- [85] Zhang X, He T, Chai Z, Samulski R J and Li C 2018 Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration *Biomaterials* **176** 71–83
- [86] Prokop A and Davidson J M 2008 Nanovehicular intracellular delivery systems *J. Pharm. Sci.* **97** 3518–90
- [87] Nunzio D, Adriana T, Valentino L, Angela L and Giuseppe T 2009 Recent advances in medicinal chemistry and pharmaceutical technology- strategies for drug delivery to the brain *Curr. Top. Med. Chem.* **9** 182–96
- [88] Salvalaio M *et al* 2016 Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders *PLoS One* **11** e0156452
- [89] Ana Rute N, Joana Fontes Q, Babette W, Ignacio A R, Pierre-Olivier C and Salette R 2015 Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E *Nanotechnology* **26** 495103
- [90] Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, He H, Yang V C and Huang Y 2016 Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for anti-glioma therapy *ACS Nano*. **10** 9999–10012
- [91] Xia H *et al* 2012 Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery *Int. J. Pharm.* **436** 840–50
- [92] Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y and Fang X 2011 Angiopep-conjugated poly(ethylene glycol)-co-poly( $\epsilon$ -caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma *Biomaterials* **32** 4293–305

- [93] Liu L, Guo K, Lu J, Venkatraman S S, Luo D, Ng K C, Ling E-A, Moomchhala S and Yang Y-Y 2008 Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier *Biomaterials* **29** 1509–17
- [94] Hua H et al 2018 RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy *Int. J. Pharm.* **543** 179–89
- [95] Kanazawa T, Kaneko M, Niide T, Akiyama F, Kakizaki S, Ibaraki H, Shiraishi S, Takashima Y, Suzuki T and Seta Y 2017 Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide *Int. J. Pharm.* **530** 195–200
- [96] Tosi G, Costantino L, Rivasi F, Ruozzi B, Leo E, Vergoni A V, Tacchi R, Bertolini A, Vandelli M A and Forni F 2007 Targeting the central nervous system: *in vivo* experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123 *J. Controlled Release* **122** 1–9
- [97] Tosi G, Fano R A, Bondioli L, Badiali L, Benassi R, Rivasi F, Ruozzi B, Forni F and Vandelli M A 2011 Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier *Nanomedicine* **6** 423–36
- [98] You L et al 2018 Targeted brain delivery of rabies virus glycoprotein 29-modified deferroxamine-loaded nanoparticles reverses functional deficits in parkinsonian mice *ACS Nano* **12** 4123–39
- [99] Gao Y, Wang Z-Y, Zhang J, Zhang Y, Huo H, Wang T, Jiang T and Wang S 2014 RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the Brain *Biomacromolecules* **15** 1010–8
- [100] Zhang E and Fu A 2015 A new strategy for specific imaging of neural cells based on peptide-conjugated gold nanoclusters *Int. J. Nanomed.* **10** 2115
- [101] Arnold A E, Czupiel P and Shoichet M 2017 Engineered polymeric nanoparticles to guide the cellular internalization and trafficking of small interfering ribonucleic acids *J. Controlled Release* **259** 3–15
- [102] Dong X 2018 Current strategies for brain drug delivery *Theranostics* **8** 1481–93
- [103] Verrecchia T, Spenlehauer G, Bazile D V, Murry-Brelier A, Archimbaud Y and Veillard M 1995 Non-stealth (poly(lactic acid/albumin) and stealth (poly(lactic acid-polyethylene glycol) nanoparticles as injectable drug carriers *J. Controlled Release* **36** 49–61
- [104] Sharma G, Modgil A, Layek B, Arora K, Sun C, Law B and Singh J 2013 Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain *in vivo*: biodistribution and transfection *J. Controlled Release* **167** 1–10
- [105] Urbisola K, Blanco-Fernández L, Ogris M, Rödl W, Wagner E and Tros de Ilarduya C 2018 Novel PAMAM-PEG-peptide conjugates for siRNA delivery targeted to the transferrin and epidermal growth factor receptors *Journal of Personalized Medicine* **8** 4
- [106] Luo Z, Jin K, Pang Q, Shen S, Yan Z, Jiang T, Zhu X, Yu L, Pang Z and Jiang X 2017 On-Demand drug release from dual-targeting small nanoparticles triggered by high-intensity focused ultrasound enhanced glioblastoma-targeting therapy *ACS Applied Materials & Interfaces* **9** 31612–25
- [107] Lu F, Pang Z, Zhao J, Jin K, Li H, Pang Q, Zhang L and Pang Z 2017 Angiopep-2-conjugated poly(ethylene glycol)-co- poly(epsilon-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats *Int J Nanomedicine* **12** 2117–27
- [108] Di Mauro P P, Cascante A, Brugada Vilà P, Gómez-Vallejo V, Llop J and Borrós S 2018 Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma *Int. J. Pharm.* **553** 169–85
- [109] Ahlschwede K M, Curran G L, Rosenberg J T, Grant S C, Sarkar G, Jenkins R B, Ramakrishnan S, Poduslo J F and Kandimalla K K 2019 Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain *Nanomed. Nanotechnol. Biol. Med.* **16** 258–66
- [110] Ghorbani M et al 2018 Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of gold-iron oxide nanocomposites: a pH-sensitive targeted drug delivery system for brain cancer theranostics *Eur. J. Pharm. Sci.* **114** 175–88
- [111] Nosrati H, Tarantash M, Bochari S, Charmi J, Bagheri Z, Fridoni M, Abdollahifar M-A, Davaran S, Danafar H and Kheiri Manjili H 2019 Glutathione (GSH) peptide conjugated magnetic nanoparticles as blood-brain barrier shuttle for MRI-monitored brain delivery of paclitaxel *ACS Biomaterials Science & Engineering* **5** 1677–85
- [112] Wang S, Zhang B, Su L, Nie W, Han D, Han G, Zhang H, Chong C and Tan J 2019 Subcellular distributions of iron oxide nanoparticles in rat brains affected by different surface modifications *Journal of Biomedical Materials Research Part A* **107** 1988–98
- [113] Albertini B et al 2019 Tumor targeting by peptide-decorated gold nanoparticles *Mol. Pharmaceutics* **16** 2430–44
- [114] Yang L, Qian W, Scott P and Shao X 2018 Towards the development of brain-penetrating gold nanoparticle-transactivator of transcription (TAT) peptide conjugates *J. Nucl. Med.* **59** 1034
- [115] Zhao L, Li Y, Zhu J, Sun N, Song N, Xing Y, Huang H and Zhao J 2019 Chlorotoxin peptide-functionalized polyethylenimine-entrapped gold nanoparticles for glioma SPECT/CT imaging and radionuclide therapy *Journal of Nanobiotechnology* **17** 30
- [116] Ivask A et al 2018 Uptake and transcytosis of functionalized superparamagnetic iron oxide nanoparticles in an *in vitro* blood brain barrier model *Biomaterials Science* **6** 314–23
- [117] Vinzant N, Scholl J L, Wu C-M, Kindle T, Koodali R and Forster G L 2017 Iron oxide nanoparticle delivery of peptides to the brain: reversal of anxiety during drug withdrawal *Frontiers in Neuroscience* **11** 608
- [118] Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Mohamadya R-T, Oupkanlou F and Hosseinkhani H 2017 Transferrin-conjugated magnetic dextran-spermine nanoparticles for targeted drug transport across blood-brain barrier *Journal of Biomedical Materials Research Part A* **105** 2851–64
- [119] Kang J, Joo J, Kwon E J, Skalak M, Hussain S, She Z-G, Ruoslahti E, Bhatia S N and Sailor M J 2016 Self-Sealing porous silicon-calcium silicate core-shell nanoparticles for targeted siRNA Delivery to the injured brain *Adv. Mater.* **28** 7962–9
- [120] Lee C, Hwang H S, Lee S, Kim B, Kim J O, Oh K T, Lee E S, Choi H-G and Youn Y S 2017 Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors *Adv. Mater.* **29** 1605563
- [121] Etame A B, Smith C A, Chan W C W and Rutka J T 2011 Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature *Nanomed. Nanotechnol. Biol. Med.* **7** 992–1000
- [122] Hanada S, Fujioka K, Inoue Y, Kanaya F, Manome Y and Yamamoto K 2014 Cell-based *in vitro* blood-brain barrier model can rapidly evaluate nanoparticles' brain permeability in association with particle size and surface modification *Int. J. Mol. Sci.* **15** 1812
- [123] Sonavane G, Tomoda K and Makino K 2008 Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size *Colloids Surf., B* **66** 274–80
- [124] Takeuchi I, Nobata S, Oiri N, Tomoda K and Makino K 2017 Biodistribution and excretion of colloidal gold nanoparticles after intravenous injection: effects of particle size *Bio-Med. Mater. Eng.* **28** 315–23
- [125] Ruff J, Hüwel S, Kogan M J, Simon U and Galla H-J 2017 The effects of gold nanoparticles functionalized with  $\beta$ -amyloid specific peptides on an *in vitro* model of blood-brain barrier *Nanomed. Nanotechnol. Biol. Med.* **13** 1645–52
- [126] Shilo M, Sharon A, Baranes K, Motiei M, Lellouche J-P M and Popovtzer R 2015 The effect of nanoparticle size on the probability to cross the blood - brain barrier: an *in-vitro* endothelial cell model (*Research*)(Report). **13** 19

- [127] Kang M H, Lee S J, Park J Y and Park J K 2018 Carbon-coated copper nanoparticles: characterization and fabrication via ultrasonic irradiation *J. Alloys Compd.* **735** 2162–6
- [128] Zhang P, Hu L, Yin Q, Zhang Z, Feng L and Li Y 2012 Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and *in vivo* evaluation *J. Controlled Release* **159** 429–34
- [129] Niu J, Wang A, Ke Z and Zheng Z 2014 Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating *J. Drug Targeting* **22** 712–23
- [130] Lopalco A, Ali H, Denora N and Rytting E 2015 Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across *in vitro* models of the blood–brain barrier and human placental trophoblast *Int. J. Nanomed.* **10** 1985–96
- [131] Haney M J *et al* 2015 Exosomes as drug delivery vehicles for Parkinson's disease therapy *J. Controlled Release* **207** 18–30
- [132] Robbins P D and Morelli A E 2014 Regulation of immune responses by extracellular vesicles *Nat. Rev. Immunol.* **14** 195
- [133] Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee J J and Lötvall J O 2007 Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells *Nat. Cell Biol.* **9** 654
- [134] Skog J, Würdinger T, van Rijn S, Meijer D H, Gainche L, Curry W T Jr, Carter B S, Krichevsky A M and Breakefield X O 2008 Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers *Nat. Cell Biol.* **10** 1470
- [135] Das C K, Jena B C, Banerjee I, das S, Parekh A, Bhutia S K and Mandal M 2018 Exosome as a novel shuttle for delivery of therapeutics across biological barriers *Mol Pharm* **16** 24–40
- [136] Yamashita T, Takahashi Y and Takakura Y 2018 Possibility of exosome-based therapeutics and challenges in production of exosomes eligible for therapeutic application *Biological & Pharmaceutical Bulletin.* **41** 835–42
- [137] Barile L and Vassalli G 2017 Exosomes: therapy delivery tools and biomarkers of diseases *Pharmacology & Therapeutics.* **174** 63–78
- [138] Ha D, Yang N and Nadihe V 2016 Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges *Acta Pharm Sin B.* **6** 287–96
- [139] Rufino-Ramos D, Albuquerque P R, Carmona V, Perfeito R, Nobre R J and Pereira de Almeida L 2017 Extracellular vesicles: novel promising delivery systems for therapy of brain diseases *J. Control. Release* **262** 247–58
- [140] Druzhkova T A and Yakovlev A A 2018 Exosome drug delivery through the blood–brain barrier: experimental approaches and potential applications *Neurochemical Journal.* **12** 195–204
- [141] Kooijmans S A, Vader P, van Dommelen S M, van Solinge W W and Schiffelers R M 2012 Exosome mimetics: a novel class of drug delivery systems *Int J Nanomedicine.* **7** 1525–41
- [142] Lu M, Xing H, Xun Z, Yang T, Zhao X, Cai C, Wang D and Ding P 2018 Functionalized extracellular vesicles as advanced therapeutic nanodelivery systems *European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences.* **121** 34–46
- [143] Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H and Sun D 2017 Engineering exosomes as refined biological nanoplateforms for drug delivery *Acta Pharmacol. Sin.* **38** 754–63
- [144] Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhil S and Wood M J A 2011 Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes *Nat. Biotechnol.* **29** 341
- [145] Tian T *et al* 2018 Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy *Biomaterials* **150** 137–49
- [146] Long Q, Upadhy D, Hattiangady B, Kim D-K, An S Y, Shuai B, Prockop D J and Shetty A K 2017 Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus *Proc. of the National Academy of Sciences* **114** E3536
- [147] Zhuang X *et al* 2011 Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain *Molecular Therapy.* **19** 1769–79
- [148] Pusic A D, Pusic K M, Clayton B L and Kraig R P 2014 IFN $\gamma$ -stimulated dendritic cell exosomes as a potential therapeutic for remyelination *Journal of neuroimmunology.* **266** 12–23
- [149] Jia G, Han Y, An Y, Ding Y, He C, Wang X and Tang Q 2018 NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma *in vitro* and *in vivo* *Biomaterials* **178** 302–16
- [150] Iraci N *et al* 2017 Extracellular vesicles are independent metabolic units with asparaginase activity *Nat. Chem. Biol.* **13** 951–5
- [151] Cooper J M, Wiklander P B O, Nordin J Z, Al-Shawi R, Wood M J, Vithlani M, Schapira A H V, Simons J P, El-Andaloussi S and Alvarez-Erviti L 2014 Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice *Movement Disorders.* **29** 1476–85
- [152] Qu M *et al* 2018 Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease *J. Controlled Release* **287** 156–66
- [153] Gui Y, Liu H, Zhang L, Lv W and Hu X 2015 Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease *Oncotarget.* **6** 37043–53
- [154] Liu Y *et al* 2015 Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse *Sci. Rep.* **5** 17543
- [155] Wu T, Yu M, Zhang L, Chen X and Pei Z 2018 I02 Systemic injection of exosomal sirna significantly reduced huntingtin expression in transgenic mice of huntington's disease *Journal of Neurology, Neurosurgery & Psychiatry.* **89** A88–9
- [156] Singh R P, Gangadharappa H V and Mruthunjaya K 2017 Phospholipids: unique carriers for drug delivery systems *J. Drug Delivery Sci. Technol.* **39** 166–79
- [157] Pulford B *et al* 2010 Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP(C) on neuronal cells and PrP(RES) in infected cell cultures *PLoS One* **5** e11085
- [158] Bender H R, Kane S and Zabel M D 2016 Delivery of therapeutic siRNA to the CNS using cationic and anionic liposomes *J. Vis. Exp.* **113**
- [159] Grinberg S, Linder C, Kolot V, Waner T, Wiesman Z, Shaubi E and Heldman E 2005 Novel cationic amphiphilic derivatives from vernonia oil: synthesis and self-aggregation into bilayer vesicles, nanoparticles, and DNA complexants *Langmuir* **21** 7638–45
- [160] Popov M, Abu Hammad I, Bachar T, Grinberg S, Linder C, Stepensky D and Heldman E 2013 Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes *Eur. J. Pharm. Biopharm.* **85** 381–9
- [161] Conceição M, Mendonça L, Nóbrega C, Gomes C, Costa P, Hirai H, Moreira J N, Lima M C, Manjunath N and Pereira de Almeida L 2016 Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype *Biomaterials* **82** 124–37
- [162] Zhang C, Gu Z, Shen L, Liu X and Lin H 2017 A dual targeting drug delivery system for penetrating blood-brain barrier and selectively delivering siRNA to neurons for alzheimer's disease treatment *Curr Pharm Biotechnol.* **18** 1124–31

- [163] Ke W, Shao K, Huang R, Han L, Liu Y, Li J, Kuang Y, Ye L, Lou J and Jiang C 2009 Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer *Biomaterials* **30** 6976–85
- [164] Al-Azzawi S, Masheta D, Guildford A, Phillips G and Santin M 2019 Designing and characterization of a novel delivery system for improved cellular uptake by brain using dendronised Apo-E-derived peptide *Frontiers in Bioengineering and Biotechnology*. **7** 49
- [165] Kang H, DeLong R, Fisher M H and Juliano R L 2005 Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides *Pharm. Res.* **22** 2099–106
- [166] Chen H T, Neerman M F, Parrish A R and Simanek E E 2004 Cytotoxicity, hemolysis, and acute *in vivo* toxicity of dendrimers based on melamine, candidate vehicles for drug delivery *J. Am. Chem. Soc.* **126** 10044–8
- [167] Perez A P, Romero E L and Morilla M J 2009 Ethylenediamine core PAMAM dendrimers/siRNA complexes as *in vitro* silencing agents *Int. J. Pharm.* **380** 189–200
- [168] Kubota Y, Sohn J, Hatada S, Schurr M, Straehle J, Gour A, Neujahr R, Miki T, Mikula S and Kawaguchi Y 2018 A carbon nanotube tape for serial-section electron microscopy of brain ultrastructure *Nat. Commun.* **9** 437
- [169] Herlem G, Picaud F, Girardet C and Micheau O 2019 Chapter 16 - carbon nanotubes: synthesis, characterization, and applications in drug-delivery systems ed S S Mohapatra (Amsterdam: Nanocarriers for Drug Delivery) pp 469–529
- [170] Costa P M, Wang J T-W, Morfin J-F, Khanum T, To W, Sosabowski J, Tóth E and Al-Jamal K T 2018 Functionalised carbon nanotubes enhance brain delivery of amyloid-targeting pittsburgh compound B (PiB)-derived ligands *Nanotheranostics*. **2** 168–83
- [171] Journet C, Maser W K, Bernier P, Loiseau A, de la Chapelle M L, Lefrant S, Deniard P, Lee R and Fischer J E 1997 Large-scale production of single-walled carbon nanotubes by the electric-arc technique *Nature* **388** 756–8
- [172] Huang Z P, Xu J W, Ren Z F, Wang J H, Siegal M P and Provencio P N 1998 Growth of highly oriented carbon nanotubes by plasma-enhanced hot filament chemical vapor deposition *Appl. Phys. Lett.* **73** 3845–7
- [173] Zhang W, Zhang Z and Zhang Y 2011 The application of carbon nanotubes in target drug delivery systems for cancer therapies *Nanoscale Res. Lett.* **6** 555
- [174] Ren J, Shen S, Wang D, Xi Z, Guo L, Pang Z, Qian Y, Sun X and Jiang X 2012 The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2 *Biomaterials* **33** 3324–33
- [175] Kafa H et al 2016 Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood–brain barrier *in vitro* and *in vivo* *J. Controlled Release* **225** 217–29
- [176] Kafa H, Wang J T-W, Rubio N, Venner K, Anderson G, Pach E, Ballesteros B, Preston J E, Abbott N J and Al-Jamal K T 2015 The interaction of carbon nanotubes with an *in vitro* blood-brain barrier model and mouse brain *in vivo* *Biomaterials* **53** 437–52
- [177] You Y, Wang N, He L, Shi C, Zhang D, Liu Y, Luo L and Chen T 2019 Designing dual-functionalized carbon nanotubes with high blood–brain-barrier permeability for precise orthotopic glioma therapy *Dalton Trans.* **48** 1569–73
- [178] Muldoon L L, Pagel M A, Kroll R A, Roman-Goldstein S, Jones R S and Neuwelt E A 1999 A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery *AJNR American Journal of Neuroradiology*. **20** 217–22
- [179] Decuzzi P, Godin B, Tanaka T, Lee S Y, Chiappini C, Liu X and Ferrari M 2010 Size and shape effects in the biodistribution of intravascularly injected particles *J. Controlled Release* **141** 320–7
- [180] Jucker B M et al 2017 Multimodal imaging approach to examine biodistribution kinetics of cabotegravir (GSK1265744) long acting parenteral formulation in rat *J. Controlled Release* **268** 102–12
- [181] Lockman P R, Koziara J M, Mumper R J and Allen D D 2004 Nanoparticle surface charges alter blood–brain barrier integrity and permeability *J. Drug Targeting* **12** 635–41
- [182] Torchilin V P 2006 Multifunctional nanocarriers *Adv. Drug Delivery Rev.* **58** 1532–55
- [183] Rassu G, Soddu E, Posadino A M, Pintus G, Sarmiento B, Giunchedi P and Gavini E 2017 Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy *Colloids Surf., B* **152** 296–301
- [184] Johnsen K B, Burkhardt A, Melander F, Kempen P J, Vejlebo J B, Siupka P, Nielsen M S, Andresen T L and Moos T 2017 Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma *Sci. Rep.* **7** 10396
- [185] Bramini M, Ye D, Hallerbach A, Nic Raghnaill M, Salvati A, Aberg C and Dawson K A 2014 Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier *ACS Nano*. **8** 4304–12
- [186] Wiley D T, Webster P, Gale A and Davis M E 2013 Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor *Proc. of the National Academy of Sciences of the United States of America* **110** 8662–7
- [187] Liu L, Xu K, Wang H, Jeremy Tan P K, Fan W, Venkatraman S S, Li L and Yang Y-Y 2009 Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent *Nat. Nanotechnol.* **4** 457
- [188] Shaki H, Ganji F, Kempen P J, Dolatshahi-Pirouz A and Vashaghani-Farahani E 2018 Self-assembled amphiphilic-dextran nanomicelles for delivery of rapamycin *J Drug Deliv Sci Technol.* **44** 333–41
- [189] Ruan H et al 2018 A novel peptide ligand RAP12 of LRP1 for glioma targeted drug delivery *J. Controlled Release* **279** 306–15
- [190] Oh J Y et al 2018 Cloaking nanoparticles with protein corona shield for targeted drug delivery *Nat. Commun.* **9** 4548
- [191] Gorshkov V, Bubis J A, Solovyeva E M, Gorshkov M V and Kjeldsen F 2019 Protein corona formed on silver nanoparticles in blood plasma is highly selective and resistant to physicochemical changes of the solution *Environmental Science: Nano*. **6** 1089–98
- [192] García-Álvarez R, Hadjidemetriou M, Sánchez-Iglesias A, Liz-Marzán L M and Kostarelos K 2018 *In vivo* formation of protein corona on gold nanoparticles *The Effect of their Size and Shape. Nanoscale*. **10** 1256–64
- [193] Nierenberg D, Khaled A R and Flores O 2018 Formation of a protein corona influences the biological identity of nanomaterials *Reports of Practical Oncology & Radiotherapy*. **23** 300–8
- [194] Phogat N, Kohl M, Uddin I and Jahan A 2018 Chapter 11 - interaction of nanoparticles with biomolecules, protein, enzymes, and its applications ed H-P Deigner and M Kohl (Cambridge, Massachusetts: Academic Press) pp 253–76
- [195] Mosquera J, García I, Henriksen-Lacey M, González-Rubio G and Liz-Marzán L M 2018 Reducing protein corona formation and enhancing colloidal stability of gold nanoparticles by capping with silica monolayers *Chem. Mater.* **31** 57–61
- [196] Walczyk D, Bombelli F B, Monopoli M P, Lynch I and Dawson K A 2010 What the cell 'sees' in bionanoscience *JACS* **132** 5761–8
- [197] Gräfe C, Weidner A, Lühe M V D, Bergemann C, Schacher F H, Clement J H and Dutz S 2016 Intentional formation of a protein corona on nanoparticles: serum concentration affects protein corona mass, surface charge, and nanoparticle–cell interaction *The International Journal of Biochemistry & Cell Biology*. **75** 196–202
- [198] Rodríguez P L, Harada T, Christian D A, Pantano D A, Tsai R K and Discher D E 2013 Minimal 'Self' peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles *Science* **339** 971–5
- [199] Fleischer C C and Payne C K 2014 Nanoparticle-cell interactions: molecular structure of the protein corona and cellular outcomes *Acc. Chem. Res.* **47** 2651–9
- [200] Lynch I and Dawson K A 2008 Protein-nanoparticle interactions *Nano Today*. **3** 40–7



- [201] Asuri P, Bale S S, Pangule R C, Shah D A, Kane R S and Dordick J S 2007 Structure, function, and stability of enzymes covalently attached to single-walled carbon nanotubes *Langmuir* **23** 12318–21
- [202] Hühn D et al 2013 Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge *ACS Nano*. **7** 3253–63
- [203] Lesniak A, Fenaroli F, Monopoli M P, Åberg C, Dawson K A and Salvati A 2012 Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells *ACS Nano*. **6** 5845–57
- [204] Maiorano G, Sabella S, Sorce B, Brunetti V, Malvindi M A, Cingolani R and Pompa P P 2010 Effects of cell culture media on the dynamic formation of protein–nanoparticle complexes and influence on the cellular response *ACS Nano*. **4** 7481–91
- [205] Monopoli M P, Walczyk D, Campbell A, Elia G, Lynch I, Baldelli Bombelli F and Dawson K A 2011 Physical–chemical aspects of protein corona: relevance to *in vitro* and *in vivo* biological impacts of nanoparticles *JACS* **133** 2525–34
- [206] Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, Schlenk F, Fischer D, Kiouptsi K and Reinhardt C 2013 Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology *Nat. Nanotechnol.* **8** 772
- [207] Bhogale A, Patel N, Mariam J, Dongre P M, Miotello A and Kothari D C 2014 Comprehensive studies on the interaction of copper nanoparticles with bovine serum albumin using various spectroscopies *Colloids Surf., B* **113** 276–84
- [208] Su G, Jiang H, Xu B, Yu Y and Chen X 2018 Effects of protein Corona on active and passive targeting of cyclic RGD peptide-functionalized pegylation nanoparticles *Mol. Pharmaceutics* **15** 5019–30
- [209] Salvati A, Pitek A S, Monopoli M P, Prapainop K, Bombelli F B, Hristov D R, Kelly P M, Åberg C, Mahon E and Dawson K A 2013 Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface *Nat. Nanotechnol.* **8** 137
- [210] Ding D, Zhang Y, Sykes E A, Chen L, Chen Z and Tan W 2019 The influence of physiological environment on the targeting effect of aptamer-guided gold nanoparticles *Nano Res.* **12** 129–35
- [211] El-Marakby E M, Hathout R M, Taha I, Mansour S and Mortada N D 2017 A novel serum-stable liver targeted cytotoxic system using valerate-conjugated chitosan nanoparticles surface decorated with glycyrrhizin *Int. J. Pharm.* **525** 123–38
- [212] Oliveira C L, Veiga F, Varela C, Roleira F, Tavares E, Silveira I and Ribeiro A J 2017 Characterization of polymeric nanoparticles for intravenous delivery: focus on stability *Colloids Surf., B* **150** 326–33
- [213] Almalik A, Alradwan I, Kalam M A and Alshamsan A 2017 Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating *Saudi Pharmaceutical Journal*. **25** 861–7
- [214] Abdelwahed W, Degobert G, Stainmesse S and Fessi H 2006 Freeze-drying of nanoparticles: formulation, process and storage considerations *Adv. Drug Delivery Rev.* **58** 1688–713
- [215] Gokce Y, Cengiz B, Yildiz N, Calimli A and Aktas Z 2014 Ultrasonication of chitosan nanoparticle suspension: influence on particle size *Colloids Surf., A* **462** 75–81
- [216] Rampino A, Borgogna M, Blasi P, Bellich B and Cesàro A 2013 Chitosan nanoparticles: preparation, size evolution and stability *Int. J. Pharm.* **455** 219–28
- [217] Cesur H, Rubinstein I, Pai A and Önyüksel H 2009 Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer *Nanomed. Nanotechnol. Biol. Med.* **5** 178–83